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Abstract 
Both chemotherapy for cancer treatment and antibiotic therapy for bacterial infections 
require systemic applications of the drug and a systemic application is always linked to a number 
of disadvantages. To circumvent these a targeted drug delivery system was developed. It utilizes 
the ability of phagocytes from the hosts own immune system to recognize and internalize 
antigens. Deactivated M. luteus, a non-pathogenic gram positive bacteria was loaded with high 
concentrations (exceeding the IC50 at least 60 fold in local intracellular concentration) the 
chemotherapeutics doxorubicin or DP44mt or with the bactericidal chlorhexidine. The modified 
bacteria is fed to phagocytes (Monocytes/Macrophages or neutrophils) and serves as protective 
shell for the transporting and targeting phagocyte. The phagocyte is recruited to the tumor site or 
site of infection and releases the drug along with the processed M. luteus via the exosome 
pathway upon arrival.  
The chlorhexidine drug delivery system was successfully tested both in vitro and in vivo, 
reducing the pathogen count and preventing systemic spread of a F. necrophorum infection in a 
mouse model. The doxorubicin drug delivery system reduced the viability of 4T1 cancer cells to 
20% over the course of four days in vitro. 
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Chapter 1 - Introduction 
The goal of this work is to utilize phagocytes, part of the unspecific immune system, to carry 
chemotherapeutics or antimicrobial drugs to the tumor or site of infection respectively. This 
targeted approach aims to circumvent a systemic application of a drug and rather relies on a high 
local concentration at the site where the drug is needed. However to avoid cytotoxic effects on 
the phagocyte by the drug and to enhance uptake the drug is first loaded into the nonpathogenic 
bacterium M. luteus. M. luteus provides a protective shell that retains the drug within the 
bacterium and enhances uptake with its antigen covered surface. The following sections aim to 
give a general overview of current drug delivery systems and to show which type of phagocyte 
and drug is suited for this application. 
 
 
Figure 1: Schematic of the proposed drug delivery system 
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 Characteristics of Tumor Physiology 
 Differences between tumor tissue and healthy tissue 
One big challenge of the cytotoxic mechanisms of non-surgical antic cancer methods is their 
non-specificity. To a certain degree both radio- and chemo- therapy are limited in their effect 
because they kill healthy cells as well. Radiation therapy tries to counteract by an increased 
precision and focus of the beam towards the tumor and its immediate surroundings. Yet these 
efforts are limited if the tumor is located deep because the surrounding tissue blocks the radiation 
dose. 
Chemotherapy drugs can achieve a degree of specificity by targeting DNA synthesis and 
therefore being more lethal to rapidly dividing cells. This however includes bone marrow cells 
(precursor cells to the immune system), hair follicles and epithelial cells of the gastrointestinal 
tract, causing severe side effects for chemotherapy patients. 
The underlying difference in solid tumors separating them from healthy tissue is the tumor 
vasculature. A tumor is supplied by two types of vessels: 
 Preexisting vessels from the healthy tissue that the tumor invaded 
 Microvessels from neovascularization as a result of proangiogenic factors secreted by the 
tumor cells 
In 1979 Endrich et al. 1) described in vivo tumor blood flow for the first time and noted its 
heterogeneity and leakiness. Structural abnormalities like wider endothelial gaps were later 
identified as the reason for the altered flow patterns 2, 3). 
The newly formed blood vessels proved to be highly irregular, including dead ends, random 
branching and a lack of smooth muscle or nerve supply 4). 
 
 Tumor Hypoxia 
Tumor hypoxia is a common feature of solid tumors in mammals 5). These hypoxic tumor areas 
can render cancer treatment ineffective, 6) for example has shown that the success of radiation 
therapy depends on the available oxygen supply. Oxygen has a diffusion distance of 
approximately 150µm with typical intercapillary oxygen tensions and oxygen consumption rates 
4). 
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Hypoxic tumor cells have also a slower rate of proliferation due to their limited oxygen supply 7, 
8) and additionally must be the most distant cells from drug distributing blood vessels. Both 
factors cause chemotherapeutics that target rapidly dividing cells to lose their effectiveness 
because on the one hand hypoxic cells are down-regulated and on the other hand the drug 
concentration drops with distance to the blood vessel. 
Two causes for hypoxia are known. The general case is the model with limited oxygen diffusion 
distance 9). Acute hypoxia can occur due to temporary obstructions of the blood flow in tumor 
blood vessels 10). Hypoxia offers new methods to attack cancer cells, for example with drugs that 
show cytotoxicity towards hypoxic cells like quinine antibiotics or nitroimidazoles 11, 12, 13). Siim 
et al. illustration demonstrates a hypothetical synergistic effect of traditional/hypoxic tumor 
treatment. 
 Cancer treatment strategies 
There are three major types of available cancer treatments. Surgery is the oldest and, if possible, 
most effective strategy since it is a zero order kinetic effectively removing the diseased cells 
from the body and therefore eliminating 100% of the thread. In contrast the other two types, 
radiotherapy and chemotherapy, can only kill a fraction of the tumor cells with each treatment 
cycle, making them effective complementary therapies. With 45% of all newly diagnosed cancer 
cases receiving radiotherapy 14) the most common therapeutic pathway is radiotherapy with 
either a complementary chemo therapy or surgery. If surgery is the complementary treatment a 
postoperative radiotherapy is preferred 15).  
 Chemotherapy 
Chemotherapy is the systemically administration of cytotoxic drugs that mostly target a cell’s 
DNA, a valid target for rapidly dividing cells like cancer cells. The drug is often administered in 
high, but not life threatening dosages called maximum tolerated dose (MTD) 16, 17). This kind of 
treatment requires extended treatment-free periods to allow the patient to recover from the side 
effects, taking the cytotoxic pressure off of surviving cancer cells and increasing the risk of the 
development of drug resistant cancer cells 18). 
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 Endocrine therapy 
Newer treatment strategies emerge as the understanding of different cancer types is improved. 
Endocrine treatments for hormone related cancers 19) such as breast and prostate cancer represent 
a new pathway to enhance traditional treatment methods. Selective estrogen inhibitors 20) and the 
newer aromatase inhibitors 21) have increased the 10 year survival rate by 11% for endocrine 
receptor positive breast cancer patients 22). 
 Targeted therapy 
Targeted therapy aims to find common targets that are universal for as many types of cancer as 
possible. There are two general types of targeting molecules: Monoclonal antibodies (mAb) and 
small molecular inhibitors. A possible route is to deplete the tumor of essential growth factors 
through binding them with specialized mAb. Anti HER-2 mAb 23) for example bind to the HER-
2/neu trans membrane receptor that is mediating cell growth, differentiation and survival. The 
HER-2/neu receptor is overexpressed in 20-25% of all breast cancer cases 24) constituting an 
especially aggressive form with short disease free periods after postoperative chemotherapy 
cycles. 
The findings led to trastuzumab, a mAb against the HER-2/neu receptor, blocking the outside 
domain and inducing an antibody dependent immune cytotoxic response 25). In cases where the 
trastuzumab treatment proved ineffective a small molecule inhibitor (lapatinib) can be used to 
inhibit the activity of the intracellular tyrosine kinase domain of the HER-2/neu receptor 26). 
 Anti-angiogenic therapy 
As the tumor growth progresses the process of angiogenesis is crucial for tumor survival and to 
avoid hypoxia and starvation 27-29). It was first hypothesized in 1971 that anti-angiogenic 
therapeutics are an effective pathway for cancer treatment 30). Angiogenesis is a process induced 
by cytokines such as VEGF, bFGF, PIGF and IL-8 and does not solely involve tumor cells. 
Surrounding tissue cells may be manipulated to produce these cytokines while the angiogenic 
process itself is carried out by cells of the immune system 31). 
A way to combat tumor angiogenesis is metronomic chemotherapy where low but frequent non-
toxic dosages (rather than the usual high and infrequent) of chemotherapeutics are applied. These 
target the endothelium of the tumor vasculature or tumor stroma rather than the tumor itself 17). 
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 Virotherapy 
Viral therapy exploits the ability of retroviruses to insert genes into a host cell. This mechanism 
can be used to manipulate tumor cells so that they express prodrug activating enzymes causing 
the administered prodrug to only become active within the tumor environment. An example is 
the use of herpes simplex in combination with the gene for thymidine kinase and the drug 
ganciclovir or cytosine deaminase with 5-fluorocytosine 32). However the immune system as well 
as a dense tumor stroma may prevent the virus from reaching all tumor cells. 
 
 Solid tumors and the immune system 
This section focusses on the relationship between cancerous cells and the immune system, most 
importantly monocytes, macrophages and neutrophils. Neutrophils make up a large portion of the 
leukocyte count fond in a wide variety of human cancers 33, 34). Neutrophil granulocytes have 
three options to take influence on tumor growth and invasiveness: 
 Chemokines and cytokines to regulate cell activity of both the tumor and the immune 
system 
 Cytotoxic reactive oxygen species (ROS). ROS have been shown to induce tumor 
establishment by causing gene-damage to host cells 35). Adversely ROS cytotoxicity has 
been shown to damage tumor cells 36) 
 Proteases for the degradation of cell-matrix or extracellular matrix proteins  
These examples underline the multilayered role of immune cells in the tumor microenvironment. 
Fridlender et al. 37) have shown that two different phenotypes of tumor associated neutrophils 
(TAN) exist. Depending on their configuration they are distinguished as TAN-N1 and TAN-N2, 
anti and pro tumor neutrophils respectively. 
The phenotype TAN-N1 shows anti-tumor activity by cytotoxicity through reactive oxygen 
species 37-39), reduced tumorigenesis by MMP-8 secretion 40), induction of apoptosis 41) and 
activation of the immune system through chemokines and cytokines 37, 42). 
TAN-N2 promotes the tumor by MMP-9 secretion (anti-apoptotic) 43, 44) Extravasation 
(collagenase, heparanase) 45-47) angiogenesis (MMP-9) 48-50) and immune suppression (arginase 
 T-cell inhibition) 51). 
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Generally the presence of (TAN) correlates with a disadvantageous prognosis as well as 
increased mortality 33, 34). An important factor associated with a high TAN count is the IL-8 level 
of a patient. High IL-8 levels correlate with both, high TAN count and poor survival 52). 
 
An important task of TANs is the remodeling of the immediate surroundings of the tumor, called 
immunosculpting or immunoediting. Here neutrophils are activated by tumor cells to remove 
healthy tissue surrounding the tumor, making space for new tumor cells 53, 54). This is achieved 
by the neutrophils wide arsenal of proteinases. These proteinases are used to degrade different 
cytokines, chemokines, integrins as well as their receptors and extracellular matrix proteins 
(collagen, elastin) to aid proliferation and angiogenesis. The most prominent proteases are 
 Neutrophil elastase: it makes up 2% of the neutrophil dry eight 55) and has a broad 
substrate specificity. It is meant to clean up cell from invading organisms or cell debris 56)  
but can also process the aforementioned protein spectrum, aiding tumor angiogenesis 57) 
 MMP-9 or gelatinase-B: neutrophil associated MMP-9 is not inhibited by TIMP-1 
molecule allowing an easier activation and a higher activity in the tumor environment 55). 
 MMP-8 
Neutrophils are actively recruited into the tumor microenvironment through IL-8 secretion by the 
tumor cells themselves. Then tumor cells can use the ICAM-1 receptor to bind to neutrophils and 
escape into circulation where they migrate to new, healthy tissues to form metastases 58). 
 
 Antibiotic and antimicrobial resistance, a global threat 
With the release of the World Health Organization’s (WHO) report on the status of antimicrobial 
resistance in April 2014 it becomes increasingly clear that the broad application of antibiotics in 
the health systems and food production cycles around the world has initiated the transition 
towards a post antibiotic era. In this scenario common diseases like pneumonia from 
Streptococcus or Klebsiella infections, diarrhea from Salmonella or Shigella infections or blood 
infections from E. coli or Staphylococcus pose a serious threat to the health system and economy 
through their acquired multi drug resistances (MDR). MDR is defined as a resistance against 
typical first line drugs (Doxycycline, Azithromycin, from CDC antibiotic treatment guidelines 
59). Diseases like Tuberculosis (TB) or cystic fibrosis have advanced even further and reached a 
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stage of extensive drug resistance (XDR). Organisms that have reached a drug resistance against 
at least one or two of the most powerful antimicrobial drugs (e.g. mycobacterium tuberculosis 
(MTB) and its resistance against fluoroquinole) are classified XDR. XDR-TB cases have been 
found in 92 countries and an estimated 6% of all TB cases are caused by MDR-TB 60). 
Pneumonia patients face an even more severe situation with XDR-pathogens against 
cephalosporin and carbapenems due to a class of enzymes called extended spectrum β-
lactamases (ESBL) 61). 
WHO has selected seven pathogens for an extensive report on and a prolonged surveillance of 
their drug resistance development. The data was compiled of the available resources from 
national official agencies, national and international antimicrobial resistance surveillance 
networks and scientific literature from 2008 on with a decreasing respective order of importance. 
WHO has also evaluated the economic impact of this threat caused by prolonged treatment 
times, decreased drug effectiveness and more sick days resulting in a loss of 20 billion $ in the 
United States alone as indicated by the 2013 CDC report. 
 Development of MDR 
Even if dosages and treatment times where sufficient, microorganisms have developed 
resistances due to the following factors: 
 Suppressed immune functions of the patient 
 Poor drug bioavailability 
 Increased drug metabolism 60) 
The pathways over which these resistances where acquired are called primary resistance (when 
the pathogen was resistant to the drug before it had contact with it) and secondary resistance. The 
secondary resistance, or acquired resistance, is developed by selective pressure on the pathogen 
after it had an encounter with the drug 62, 63). It can be divided in three sub-categories depending 
on their severity: 
 Intrinsic resistance or MDR. Characterized by a resistance against first line drugs (e.g. 
rifampicine or fluconazole 62) 
 Extensive resistance. Characterized by a resistance against the most powerful 
antimicrobials (e.g. fluoroquinole 64,65)) 
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 Clinical resistance. This is the case if the invading pathogen is only inhibited by drug 
concentrations higher than the MTD 62) 
The general mechanisms of action of antibiotic drugs are inhibition of metabolic pathways like 
nucleotide synthesis, DNA/RNA synthesis or protein synthesis as well as a competition with the 
substrates for cell wall synthesis for enzymes like chitin synthase 66). The problem with 
mechanisms that target the biochemistry of the cell is that mutations in the genome and the 
selective pressure on the pathogen population bare the risk that pathogens develop appropriate 
countermeasures 60). These may include alterations in the membrane composition that reduce 
permeability, uptake and susceptibility to antibiotics 62, 66, 67). An example is the reduced 
ergosterol content in fungal plasma membranes. Gene mutations in genes that encode the 
targeted protein can lead to structural changes in the protein’s 3D configuration of the peptide 
chain. While the proteins biochemical function is retained, this can cause decreased susceptibility 
to the drug because the new conformation hinders the drug-protein interaction 62, 66, 68). Or the 
pathogen starts an overexpression of the drug target to bypass inhibition 69). 
A more active form of pathogen defense against antibiotics is the expression of enzymes that 
inactivate or degrade the drug by ester- or amide-bond formation in the drug molecule or 
acetylation, phosphorylation, adenylation, glycosylation and hydroxylation 60) 
 Drug delivery systems (DDS) 
Traditional chemo-therapy as well as antibiotic treatments rely on a systemic administration of 
the drug. This system has the flaw that large quantities of the active component are required to 
achieve therapeutic concentration at the diseased site. A systemic application also means that the 
drug reaches healthy regions of the host body possibly leading to severe side effects. Targeted 
drug therapy follows the idea to confine and focus the drug distribution to the diseased area as 
much as possible. The market has 30 main drug delivery products available and generates 33$ 
billion annual revenue with an estimated annual growth of 15% 70). Current technologies can be 
split in two groups: 
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Soluble macromolecules 
 Monoclonal antibodies 
 Soluble synthetic polymers 
 Polysaccharides 
 Biodegradable polymers 
Complex particulate multicomponent structures 
 Microcapsules/-particles 
 Lipoproteins 
 Liposomes 
 Cell ghosts 
 Cells 
A hypothetical ideal drug delivery system is the pharmacyte, a nanorobot capable of delivering 
drugs directly to the diseased cell 71). With current technology a cell based drug delivery 
approach is the closest available targeting system 72). 
The following sections are intended to give an overview of current synthetic and cell based drug 
delivery systems. 
 Liposomes and similar particulate carriers 
Macromolecular carriers are limited in their drug carrying capacity (1:1 ratio for 
immunoconjugates and 1:10 ratio for polymer conjugates) and therefore require more potent 
drugs since higher dosages of carrier material aren’t always an option due to the risk of carrier 
toxicity 73). Liposomes don’t face this problem due to their super-molecular structure and usually 
provide carrier to drug ratios of 1:10000 unless the liposome is designed very small for enhanced 
biodistribution (BD) while a large therapeutic molecule such as a protein is the payload 74). On 
the other hand liposome systems, while offering good retention characteristics for hydrophilic 
molecules, may struggle with the retention of neutral hydrophobic intermediate solubility drugs 
75). Macromolecular carrier-drug conjugates don’t face this problem since the drug is generally 
covalently linked to the carrier 76). To overcome this hurdle pH or chemical gradients can help 
with loading and retaining drugs like doxorubicin or vincristine into liposomes 77, 78). 
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Early generation liposomes were detected by the immune system and the majority were captured 
by the reticuloendothelial system (RES) of the liver. Polyethylene glycol (PEG) coated 
liposomes brought a major improvement with a loss of only 10%-15% to the RES 79). 
General positive effects of carrier systems are a decreased drug clearance and in consequence an 
increased half-life of the drug. The volume of distribution decreases, possibly minimizing side 
effects on healthy body parts and the area under the concentration versus time curve increases, 
granting a prolonged time over the minimal therapeutic concentration (MTC). 76). 
The rate of drug release from a larger (50-200nm) liposomal carrier is detrimental for the drugs 
BD pattern. A slow drug release confines the drug’s pharmacokinetics (PK) and BD 
approximately to the volume of plasma, giving it the same pattern as for the carrier itself while a 
rapid release shifts the PK and BD towards the pattern of a free drug, although improvements in 
unwanted toxicity may be seen 80). A too slow rate of release may lead to an impaired therapeutic 
effect when compared to the free drug due to drug concentrations under the MTC 81). Most actual 
systems are in between those two extremes, making the rate of drug release the major balancing 
factor for the drugs PK and BD 76). 
The use of a liposomal carrier can also affect the maximum tolerated dose (MTD) in three 
possible ways: 
 MTD is increased (e.g. the kidney toxicity of amphotericin B can be controlled when 
administered in a liposomal carrier, leading to larger quantities of amphotericin B 82) 
 MTD stays the same (e.g. liposomal vincistrine where the MTD stays the same while the 
drugs potency is increased 83) 
 MTD is decreased (e.g. liposomal carriers protect topodecan from metabolization, 
lowering the amount that can be administered without severe toxic side effects 84) 
A special case are drugs that are inactive while associated with the carrier. For example 
doxorubicin linked to N2-hydroxypropyl methacrylamide copolymers leads to a large increase of 
the MTD due to reduced cardiotoxicity 85). 
 Enhanced Permeability and Retention (EPR) effect 
EPR is a passive targeting effect for larger particulate carriers 86). Certain pathological conditions 
like inflammation or solid tumors increase the permeability of the tissue vasculature by widening 
the gap size (up to 600-800nm) between the endothelial cells. This allows larger carriers that 
11 
 
would normally be retained in the blood stream to escape the blood vessel into the tissue 
environment 87). This condition is induced by cytokines released from inflamed or tumorous 
tissue to allow leukocyte extravasation for an immune/inflammatory or tumor angiogenesis 
response respectively 88, 89). 
 
Especially in tumors the combination of the EPR effect with an impaired lymphatic drainage of 
the tumor tissue can lead to a concentration of carrier particles in the interstitial regions of the 
tumor environment of up to ten fold 90, 91, 92, 93) The EPR effect does however not guarantee a 
homogeneous distribution of the carrier particles within the tumor or inflammatory site. It is not 
yet fully understood what causes this rather focal distribution of carrier particles 94). Several 
factors have been identified playing a role in carrier distribution throughout the target area 76): 
 Average size of the drug delivery systems (DDS) particles 
 DDS half-life in circulation (DDS particle concentration peaks at the tumor site 1-3 days 
after the injection) 
 Degree of tumor vascularization 
 Degree of angiogenesis 
 Epithelial pore size 
With the rate and level of bioavailable drug as a detrimental factor for a successful DDS therapy 
relying on the EPR effect a long carrier half-life is desirable to ensure an optimal accumulation 
of carrier particles in the diseased tissue 95). The strong dependence of DDS on rate and amount 
of released drug lead to further developments such as triggered release mechanisms or the 
delivery of prodrugs in combination with drug activating signals. Examples for investigated 
triggered release mechanisms are pH or temperature shifts, magnetic fields, sensitivities to 
specific enzyme levels and radiofrequency 96, 97). An example for an activatable prodrug is 
Visudyne in combination with the liposomal photosensitizer verteporfin 98). 
Some carrier systems do not rely on the EPR effect but rather on a sustained drug release into 
blood circulation. This system is comparable to an IV drug infusion but with less inconvenience 
for the patient 99). 
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 Active targeting systems for synthetic delivery systems 
The most recent efforts in DDS research have focused on the use of targeting moieties on the 
surface of carrier particles. These targeting moieties, mostly short signaling peptides, are 
intended to increase the site specific action of the DDS (“Ligand mediated targeting”) by adding 
an active targeting mechanism to the system rather than to rely on the passive EPR effect 73). 
 Cell based drug delivery systems 
 Monocytes and macrophages 
Drug delivery systems that are based on live, biologically active cells exist in two forms: 
Transduced cells, which are genetically altered to express the pharmaceutically relevant 
molecules and cell carriers that are loaded with drugs and are intended to release the drug either 
in circulation or at a specific site they target 70). 
Examples for transduced cells are monocytes and macrophages that deliver immunomodulatory 
molecules at the site of interest 100) or stem-cells that have targeted brain metastases from 
melanoma 101). 
Macrophages and monocytes have been investigated as drug carriers 102, 103). After an ex vivo 
loading with an antiretroviral drug the macrophages were observed in lung, liver, kidney and 
spleen. HIV-Ip 24 antigen levels were reduced by 23-51%. 
The loading of macrophages with nanoparticulate drug carriers has also been investigated 104-113) 
revealing several possible uptake routes for carrier types: 
 Polysaccharides 114) 
 Endotoxins 115) 
 Immunoglobulins (via the Fc receptor) 116) 
 Low density lipids (LDL, via scavenger receptors) 117) 
Depending on the receptor pathway of the uptake of particulate nanomaterials the monocytes 
reaction may alter, having an influence of endosome maturation, endosome-lysosome fusion and 
inflammatory response 108). This may affect parameters such as drug release, metabolism and 
bioavailability. 
The characteristics of particulate carriers play an important role for the readiness of macrophages 
to take them up 119, 120): 
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 Surface charge of the particle (negative surface charge is beneficial for uptake) 
 Hydrophobicity 
 Morphology 
 Chemical structure 
Overloading monocytes with nanoparticulate carriers may lead to cell death via respiratory burst 
121, 122). 
Another example of cell based drug delivery is the encapsulation of catalase by monocytes. The 
enzyme is intended to combat reactive oxygen species at inflammatory sits in atherosclerosis 
patients 123). 
 Erythrocytes 
Since erythrocytes that have exceeded their life span are recycled by monocytes/macrophages in 
liver and spleen they can be used to target specifically these cell types to treat diseases like 
Leishmaniasis 70). Old erythrocytes are recognized via the reticuloendothelial system (RES) by 
monocytes and macrophages. If erythrocytes are used as a DDS the RES-signal can be 
artificially induced for loaded erythrocytes to trigger a rapid uptake and drug delivery to the 
monocytes and macrophages 124, 125). The loading mechanism for erythrocytes relies on osmotic 
pressure to conserve the functionality and integrity of the cell which in turn limits the range of 
drugs that can be loaded to water soluble molecules. 
 Bacterial ghosts 
Bacterial ghosts are bacterial cells with a genetically induced pore that causes the depletion of all 
cytoplasm and its contents while surface antigenicity and morphology are conserved. The ghost 
cell can then be loaded with chemotherapeutics or immunoglobulins targeting tumors. Due to the 
large pore size this DDS is limited to molecules that associate strongly with the bacterial 
membrane, membrane proteins or cell wall to achieve acceptable retention of the drug 126, 127). 
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 Summary 
DDS have been criticized for their complexity and higher costs, however microparticulate 
systems not involving viruses or transduced cells can be cost competitive 128) especially when 
toxicity management and side effect mediation are considered 129, 130). Negative side effects off 
DDS are possible hypersensitivity 131), a reaction of the immune system against the carrier and/or 
drug 132) and possible stronger drug side effects due to an altered PK and BD 133,134). 
 
 Phagocytes 
 Discovery and sub-classification 
Phagocytic cells are part of the mammalian immune system. Their primary task is to protect the 
host organism from harmful invading foreign objects (e.g. Viruses, bacteria, fungi, parasites, 
toxins) by ingestion of the invaders 135). They are the higher organism’s first line of defense in 
the fight against any infection and help in the development of the immune systems specific 
response and subsequent immunity via antigen presentation 136). Their antibacterial properties 
were first discovered by Nobel Prize laureate Ilya Mechnikov in 1882 137). 
Phagocytes can be categorized into two sub groups, professional and non-professional 
phagocytes 138, 139). Examples for professional phagocytes are: 
 Neutrophil granulocytes 
 Monocytes/Macrophages 
 Mast cells 
 Dendritic cells 
While non-professional phagocytes are represented by: 
 Lymphocytes 
 Epithelial cells 
 Natural killer cells 
 Endothelial cells 
 Fibroblasts 
 Erythrocytes 
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The differentiation of the two sub groups is based on the presence of specialized receptors (e.g. 
IgG Fc receptors (FcγR) and complement receptors) that can recognize and bind foreign objects 
which present antigens on their surface 140). These receptors can only be found in professional 
phagocytes. 
 Available antibacterial and antiviral pathways 
In case of an infection phagocytes are recruited from the blood stream into the inflamed tissue by 
a chemical signal cascade called chemotaxis 141,142). The signaling molecules, chemokines, can 
originate from the invading organism, the invaded tissue or phagocytes already present at the site 
of the infection 143). The chemokines then create a concentration gradient that the phagocytes 
travel along towards its origin. Notable chemokines are: 
 Interleukin 8 (IL-8) for neutrophils 144, 145) 
 Chemokine ligand 5 (CCL5) for monocytes and macrophages 144, 145) 
 
After arrival at the site of inflammation and upon contact with the pathogen phagocytes begin the 
engulfment of the foreign organism. This process is called endocytosis 144). Phagocytes then can 
kill the internalized organism with reactive oxygen species or nitric oxide 146).  Some phagocytes 
are specialized to present parts of the digested pathogen on their cell-surface to other cells of the 
immune system. This triggers the specific immune response and leads to the mass production of 
monoclonal antibodies (mAb) by lymphocytes, specifically tailored to the invading pathogen 147). 
Phagocytes can rely on three different ways to kill or inactivate pathogens 148): 
 Oxygen dependent intracellular 
 Oxygen independent intracellular 
 Extracellular 
The oxygen dependent intracellular pathway, or respiratory burst, is characterized by an 
increased oxygen uptake of the phagocyte upon endocytosis of the pathogen 149). The produced 
reactive oxygen species are toxic to both, the invading cell and the phagocyte and therefore 
require compartmentalization to minimize host cell damage. There are two types of reactive 
oxygen species used by phagocytes. The first type, superoxide (O2
-) 150), is enzymatically 
converted by superoxide dismutase to hydrogen peroxide (H2O2) 
151, 152). Furthermore superoxide 
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and H2O2 can produce hydroxyl radicals (HO) that assist in killing the pathogen. The second type 
is solely used by neutrophil granulocytes and results in the formation of hypochlorite (=bleach) 
by myeloperoxidase 153). The oxygen dependent intracellular pathway is the most effective tool 
of phagocytes against invading pathogens. 
The oxygen independent pathway is not as effective but knows four different types: 
 Charged peptides that damage the membrane of endocytosed bacteria 154) 
 Lysozyme, an enzyme specialized in breaking down bacterial cell walls 155)  
 Lactoferrins that deplete the bacterium of essential iron 156) 
 Proteases and hydrolases that digest bacterial proteins 157)  
This pathway is activated once the endosome fuses with the lysosome, a vesicle containing these 
different types of digestive enzymes. 
The extracellular killing pathway relies on the release of nitric oxide (NO) by the phagocyte into 
the extracellular medium. Nitric oxide is produced enzymatically produced by interferon-gamma 
(IFNγ) stimulated macrophages and causes DNA damage to the pathogen by de-aminating its 
nucleobases. Cells secreting the IFNγ stimulant are T-cells, B-cells, natural killer cells, 
monocytes, dendritic cells and other macrophages 158). 
Activated macrophages also produce tumor necrosis factor (TNF), a signaling molecule that can 
induce apoptosis to cancer cells or virus infected cells in the immediate environment of the 
macrophage 159). 
 Activation of phagocytes 
Phagocytes exist in varying degrees of readiness throughout the body and require different 
activation pathways to reach their full anti-pathogenic potential. Macrophages for example 
usually exist in a semi resting state in anchored positions throughout the tissue. In case of an 
infection they are activated and recruited to the infection site by IFNγ emitted from the infected 
host cells 160). Additional macrophages can be recruited by the attraction of monocytes from the 
bloodstream that differentiate to macrophages upon the arrival at the inflammation site. This 
recruitment process occurs in a timeframe of several hours to a day 161).  However in case of a 
sudden direct contact with a pathogens endotoxins in combination with high levels of IFNγ, 
macrophages become hyper-activated causing them so solely focus on an increased phagocytic 
activity 162). 
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Neutrophils primarily float with the blood stream until activated by signaling molecules (mostly 
IL-8) emitted from inflamed tissue or responding tissue anchored macrophages. Once activated 
they leave the bloodstream through endothelial gaps, responding to an invading organism within 
minutes making them the first line of defense in the unspecific immune response 163). 
In this work we specifically investigated the role of Monocytes, Macrophages and most 
importantly neutrophils as a targeting component in a cancer or anti-bacterial drug delivery 
system. The following section will provide more detailed information on these three phagocyte 
cell types. 
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Chapter 2 - Cell-Types and Active Components Used in the Drug 
Delivery System 
 
 Monocytes 
Monocytes represent the largest type of white blood cell and constitute 2%-10% 164) of all white 
blood cells. Upon activation they respond to inflammatory signals within 6-18 hours 165) via 
extravasation from the blood stream and tissue migration. Upon arrival at the infection site they 
differentiate into macrophages or dendritic cells 166), fulfilling three main functions: 
 Phagocytosis 
 Antigen presentation to trigger a specific immune response 
 Cytokine production (TFN, IL-1, IL-12) to recruit other immune cells to the infection 
site 
There exist three different phenotypes of monocytes characterized by various levels of CD14 
and CD 16 surface receptors. CD14 serves as a receptor for bacterial antigen recognition 
while CD16 is involved in the activation of natural killer cells 167). 
 Macrophages 
The name macrophage means big eater and describes their primary role in the unspecific immune 
response. With an average diameter of 21.2 ± 0.3µm 168) they are able to phagocytize invading 
foreign organisms and particles up to a size of 20µm 169). After phagocytosis macrophages can 
present parts of the digested and processed invading organism 170) to CD4+ T-cells that regulate 
the activity of the adaptive immune system for a specific immune response 171), most essentially 
B-cell antibody class switching. The macrophage presents the processed antigen (usually a 
surface protein of the pathogen) on an MHC class II receptor (major histocompatibility complex) 
172). 
Macrophages have the unique ability to metabolize arginine for the production of nitric oxide, 
used as an extracellular bactericidal molecule. Alternatively ornithine, a cellular repair molecule 
is produced which allows the differentiation of macrophages into two sub categories: M1 
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macrophages or “killer macrophages” which secrete the pro-inflammatory IL-12 or M2 “repair 
macrophages” which secrete the anti-inflammatory IL-10 173). 
 The Macrophage life cycle 
The life cycle of a macrophage begins when a monocyte is triggered to leave the bloodstream. 
With that it starts the differentiation process towards a macrophage. Unlike the short lived 
neutrophils, macrophages have a survival time of several months if they are semi dormant and 
anchored in tissue 174). While at this stage their primary role is to clean up dead host cells and 
host cell debris like aged neutrophils via the CD31 receptor 175, 176). 
Once a macrophage responds to inflammatory signals sent out by inflamed tissue or neutrophil 
first responders it becomes mobile and starts to migrate towards the origin of inflammation using 
pseudopods in an amoeboid movement 177, 178). Activated macrophages have an average life time 
of 15 days. 
 Neutrophil granulocytes 
Neutrophil granulocytes are the immune system’s first response to an invading organism 179). 
They have a short average life time of 5.4 days in their dormant stage 180) (although this value is 
also reported as 24-48h 179, 181) and disputed claiming a life span 10 hours in blood circulation 
elsewhere 182) and exhibit a very high motility enabling them to respond to inflammatory signals 
and reaching the inflamed tissue region within minutes 183). They represent the most abundant 
white blood cell type with approximately 50-70% of all white blood cells being neutrophils 184). 
With a spherical shape their size ranges from 8-12µm when dormant 185) and approximately 
16·1010 neutrophils are produced daily in humans 186, 187). The most important molecule class for 
neutrophil activation and recruitment are cytokines with IL-8 and IFNγ as the most prominent 
examples. When activated via chemotaxis the neutrophils extravasate from the blood stream and 
fight the invading pathogen at the source of inflammation for 1-2 days. The short lifetime may be 
intended to limit propagation of parasitic bacteria as well as damage to the host tissue by 
antimicrobial products during inflammatory neutrophil response 188). 
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Neutrophils are specialized in the fight against pathogenic microbes and have three ways to fight 
infections: 
 Phagocytosis and respiratory burst 
 Release of soluble antimicrobial granules 189-191) 
 Neutrophil extracellular traps (NETs) 192) 
While the phagocytic pathway works similar as in the previously discussed macrophages the 
other two ways are unique to neutrophils. Antimicrobial granules can be categorized as primary, 
secondary and tertiary granules 189). 
Primary granules contain peroxidases, bactericidal/permeability increasing protein (BPI), 
defensing, serine proteases and cathepsin G. Secondary granules contain alkaline phosphatase, 
lysozyme, collagenase and lactoferrin. Tertiary granules contain cathepsines and gelatinase189-
191). 
Neutrophil extracellular traps were discovered fairly recently in 2004 and are antimicrobial 
proteins distributed on a DNA scaffold designed to entrap and immobilize pathogens. 
Macrophages, as the secondary wave of the unspecific immune response then clean up the NETs 
along with entrapped bacteria or fungi upon their arrival at the site of inflammation 192). 
 Active Components 
 DPP44mt 
DP44mt is an iron and copper chelator designed for anti-tumor activity. Buss et al and 
Kalinowski et al 193, 194) have shown that depriving a solid tumor of the essential nutrient and 
physiological trace element iron can inhibit the growth of cancer cells and iron chelating drugs 
like Triapine have entered clinical trials 195). This is of particular interest since cytotoxic iron 
chelators like DP44mt don’t rely on the apoptosis inducing factor p53 196), that is often defective 
in a wide variety of cancer cells 197, 198, 199). The rate limiting step of DNA-synthesis for example 
is catalyzed by ribonucleotide reductase, an enzyme relying on iron to remain active 200). 
Richadson et al. 201) have developed a new class of di-2-pyridylketone thiosemicarbazones (DpT 
backbone) of which DP44mt (di-2-pyridylketone-4, 4-dimethyl-3-thiosemicarbazone) showed 
the most promising results in vitro. In a study with 28 different cancer cell types DP44mt’s 
average IC50 was 0.03 ± 0.01 µM with a range from 0.005 to 0.4 µM. These results were 
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significantly lower than the IC50 for Triapine (1.41 ± 0.37 µM) or DOX (0.62 ± 0.35 µM, range 
0.02-0.6 µM) and DP44mt outperformed DOX on 26 out of 28 cell lines 201). 
In addition to the inhibition of iron-dependent enzymes DP44mt has shown to up-regulate the N-
myc downstream regulated gene I (NdrgI) 202), a gene known to inhibit primary tumor growth 
and the formation of metastasis 203). 
However due to its high cytotoxicity DP44mt can induce cardiac fibrosis in a dose dependent 
manner (doses above 0.75 mg/kg, 201). This effect might be mediated with appropriate dosing of 
the drug (it shows significant tumor growth inhibition at 0.3 mg/kg 204. 
Further investigation of DP44mt’s mechanism of action showed that the drug can chelate both, 
iron 205) and copper 206) ions. Both complexes have redox potential and attack the lysosomal 
membrane 207). The copper complex shows greater activity than the iron complex or the DP44mt 
ligand alone but copper is not successfully scavenged from the tumor cells 207). The drug could 
be administered in its copper complex form to exploit the higher activity.  
 
 Doxorubicin 
Doxorubicin, also called Adriamycin, is an anthracycline antibiotic 208). Its effectiveness in 
cancer treatment has been studied for both animals 209) and humans 210). Doxorubicin binds to 
free nucleic acids and inhibits DNA- and RNA polymerases 211-213) which results in a blocked 
DNA or RNA synthesis and cell death for fast proliferating cells. Its application is limited by a 
dose dependent cardiac dysfunction 214). 
 Chlorhexidine 
Chlorhexidine is a bactericidal and bacteriostatic as well as a topical disinfectant. It is commonly 
used in mouthwash and contact lens cleaning solutions and its mechanism of action is membrane 
disruption 215, 216). The positively charged drug recognizes bacteria by their overall negative 
surface charge from the cell wall molecules, and attaches to the bacterial surface. Then it begins 
with the disruption of parts of both cell –wall and membrane causing leakage of the cytoplasm 
and uncontrolled ion flow that ultimately lead to the bacteria’s death. Its IC50 varies depending 
on the attacked organism but lies between 0.01 and 0.1 Mg/kg (CHX MSDS sheet). Because of 
this rather physical then biochemical approach especially gram positive microorganisms (like 
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MRSA) have difficulties do develop effective countermeasures and resistances, although rises in 
the minimum inhibitory concentration may be observed 217, 218). 
Chlorhexidine is in the WHO list of essential medicines (WHO Model List of Essential 
Medicines, 18th list, April 2013) 
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Chapter 3 - Abbreviations 
ATCC - American Type Culture Collection 
BD - Biodistribution 
bFGF - Basic fibroblast growth factor 
BPI - Bactericidal/permeability increasing protein 
CCL - Chemokine ligand 
CD receptor - Classification determinant receptor 
CDC - Centers for Disease Control and Prevention 
CFU - Colony forming unit 
CHX - Chlorhexidine 
DDS - Drug delivery system 
DIEA - N,N-Diisopropylethylamine 
DMF - Dimethylformamine 
DMSO - Dimethyl sulfoxide 
DNA - Deoxyribonucleic acid 
DOX - Doxorubicin 
DOXY - Doxycycline 
EDC - 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EPR - Enhanced permeability and retention 
ESBL - Extended spectrum β-lactamases 
HER-2/neu - Receptor tyrosine-protein kinase erbB-2 
HIV - Human immunodeficiency virus 
HOBT - Hydroxybenzotriazole 
IC - Inhibitory concentration 
IFNγ - Interferon gamma 
IgG - Immunoglobulin G 
IL - Interleukin 
IV - Intravenous 
IVIS - In vivo imaging system 
LDL - Low density lipid 
24 
 
mAb - Monoclonal antibody 
MDR - multi drug resistant 
ML - Micrococcus luteus 
MMP -  Matrix metalloproteinase 
MOI - Multiplicity of infection 
MPN - Most probable number 
MRSA - Multiresistant Staphylococcus aureus 
MSDS - Material safety data sheet 
MTC - Minimal therapeutic concentration 
MTD - Maximum tolerated dose 
MTT - 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NdrgI - N-myc downstream regulated gene 
NETs - Neutrophil extracellular traps 
OD - Optical density 
PBS - Phosphate buffered saline 
PEG - Polyethylene glycol 
PI - Propidium Iodide 
PIGF - Phosphatidylinositol-glycan biosynthesis class F protein 
PK - Pharmacokinetics 
PMN - Polymorphonuclear neutrophils 
PRAS-BHI - Pre Reduced Anaerobically Sterilized Brain Heart Infusion broth 
RES - Reticuloendothelial system 
RNA - Ribonucleic acid 
ROS - Reactive oxygen species 
rpm - revolutions per minute 
RPMI - Roswell Park Memorial Institute 
SDS - Sodium dodecyl sulfate 
TAN - Tumor associated neutrophils 
TB - Tuberculosis 
TNF - Tumor necrosis factor 
UV/Vis - Ultraviolet/Visible 
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VEGF - Vascular endothelial growth factor 
WHO - World Health Organization 
XDR - Extensive drug resistance 
 
Chapter 4 - Materials and Methods 
 Materials 
Chlorhexidine-gluconate (CHX, 2% solution, MW: 897.75 g/mol) was purchased from Bimeda 
(IL). Chlorhexidine-diacetate hydrate (>98% purity, MW: 625.55 g/mol) was purchased from 
Acros Organics (NJ). Doxorubicin-hydrochloride (DOX, >99% purity, MW: 579.98 g/mol was 
purchased from TSZ Chem (MA). DP44mt was synthesized by Dr. Tej B. Shrestha 204). 
Doxycycline (DOXY, >99% purity, MW: 444.43 g/mol) was purchased from Clontech (CA). 
LB-broth, Miller was purchased from Acros Organics (NJ). RPMI1640 medium was purchased 
from Sigma-Aldrich (MO). PI/Annexin V dead cell apoptosis kit for flow cytometry was 
purchased from lifetechnologies (NY). Rhodamine-B (analytical grade, MW: 479.02 g/mol) was 
purchased from Fisher Chemical (MA). All other chemicals were purchased of analytical grade. 
Micrococcus luteus was purchased from Carolina Biological Supply Company (NC). RAW 
264.7 Monocyte/Macrophage co-culture (Mo/Ma cells) was purchased from American Type 
Culture Collection (ATCC) (VA). 4T1luc2 cancer cell line was purchased from Caliper Life 
Sciences (MA). 
 Buffers 
 PBS 
Concentrated 10x PBS stock solution was made by dissolving 79g NaCl, 3.4g KCl, 14.4g 
Na2HPO4 and 2.4g KH2PO4 in 1000ml of purified water (B-Pure Water Purification System, 
Barnstead, Van Nuys, CA). After complete dissolution of all material the pH was adjusted to 7.4 
using NaOH (pH meter: Orion 2 Star, Thermo Scientific, Waltham, MA). To reach the 1x 
working concentration 100ml of 10x PBS were mixed with 900ml of purified water. 
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 Lysis Buffer 
Lysis buffer was made by dissolving 6.057g (50mM) of Tris in 1000ml of purified water. After 
the complete dissolution of Tris, 1% (w/v) Triton-X 100 was added and the pH was adjusted to 
7.4.  
 Strong Lysis Buffer 
Strong lysis buffer is a modification of lysis buffer with 3% (w/v) Triton-X 100 and 1% (w/v) 
SDS added to the buffer and the pH adjusted to 7.4. 
 M. luteus Culture 
In a 225ml KIMAX culture flask 2g LB broth substrate were dissolved in 100ml purified water 
and autoclaved for 45 min at 121°C and 1bar (Autoclave: Yamato Sterilizer SM200, Japan). The 
sterile medium was inoculated with 100 µl of a M. luteus suspension and the culture was grown 
for 12 hours at 37 °C and 200 rpm (New Brunswick scientific heated shaker, Enfield, CT). The 
cells were separated from the medium via centrifugation at 10000g (Thermo Scientific Sorvall 
Legend RT+ centrifuge, Waltham, MA) and washed twice with phosphate buffered saline (PBS) 
by replacing the supernatant with fresh buffer and resuspending the cells through vortexing. To 
proceed with the loading of the various active components, 1 ml of the cell suspension was 
transferred into a 1.5 ml Eppendorf reaction tube and centrifuged at 14000 rpm (Eppendorf 
centrifuge 5415C, Germany). The supernatant was removed so that the cell pellet was ready for 
resuspension in a solution of the respective active component. This procedure was repeated for 
the desired number of samples. 
 Loading of M. Luteus with Chlorhexidine 
To load M. luteus with chlorhexidine, the cell pellet of 1 ml cell-suspension was resuspended in 
concentrated chlorhexidine-gluconate (the stock solution is 2% w/v). A total of 5 samples was 
prepared. The chlorhexidine-cell suspension was placed on the thermo rocker overnight. After 
12-18 hours the samples were centrifuged at 14000rpm, washed with PBS once and both 
supernatant and cell pellet were kept for further analysis. 
An initial characterization of loaded and unloaded M. luteus suspensions was done using the 
UV/Vis plate reader (Synergy H1 micro-plate reader BioTek, Winooski, VT) and analysis 
software Gen5 v2.05 (BioTek Winooski, VT). The absorbance spectrum for five loaded and five 
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unloaded samples of M. luteus were measured by plating 100µl of the respective samples in 
wells on a 96 well plate and measuring the absorbance in the region from 550nm to 700nm with 
a 2nm step size. 
To quantify the amount of CHX taken up by M. luteus two methods were employed: An indirect 
measurement that keeps the actual cell-sample intact for further experiments and a direct 
measurement where CHX is released from the cells by disrupting the cells with lysis buffer. 
 Indirect measurement 
M. luteus cells were loaded with CHX as previously described. After loading the cells were 
separated from the remaining CHX stock solution (loading supernatant) by centrifuging at 
14000rpm. The absorbance spectrum of the loading supernatant was measured from 550 to 700 
nm. The absorption peak of CHX occurring at 635 nm was used for calibration and data analysis. 
The loading supernatant’s absorbance at 635nm is analyzed using UV/Vis spectroscopy and 
compared to the absorbance of unaltered CHX stock solution at 635nm. 
 
Figure 2: Example for the setup of the 96 well plate for UV/Vis analysis 
 
 The supernatant is expected to have a significantly lower absorbance in comparison to the stock 
solution and the amount of CHX accumulated in the cells can be calculated via spectral 
subtraction. 
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 Direct measurement 
M. luteus cells were loaded with CHX as previously described. The cells were separated from the 
remaining CHX solution via centrifugation at 14000rpm and washed with PBS. To measure 
intracellular CHX directly the samples were centrifuged at 14000rpm and the cell pellet was 
resuspended in 1 ml lysis buffer and placed in a 40 °C sonication water bath for 30 minutes. The 
cell fragments were centrifuged off subsequently and the supernatant was removed. Cell 
fragments were resuspended in 1 ml PBS buffer and both the cell fragment suspension as well as 
the lysate were analyzed for their CHX concentration. The absorbance spectra were measured 
from 550 to 700 nm. The absorption peak of CHX occurring at 635 nm was used for data 
analysis. 
 Time Resolved Loading of CHX 
M. luteus cells were loaded as previously described with the modification that the loading time 
was controlled and 1, 2, 3 and 4 hours of loading were allowed for the respective samples. The 
cells were separated from the remaining CHX solution via centrifugation at 14000rpm after the 
defined loading time was up and washed with PBS. To measure intracellular CHX directly the 
samples were centrifuged at 14000rpm and the cell pellet was resuspended in 1 ml lysis buffer 
and placed in a 40 °C sonication water bath for 30 minutes. The cell fragments were centrifuged 
off subsequently and the supernatant was removed. The absorbance spectra of the supernatant 
was measured from 550 to 700 nm. The absorption peak of CHX occurring at 635 nm was used 
for data analysis. 
 Zeta Potential Measurements 
A dilution series of a 1000µg/ml CHX-diacetate stock solution in PBS was produced to acquire 
the desired concentrations and M. luteus was loaded as previously described with the serial 
dilution of CHX-diacetate instead of CHX-gluconate stock solution. A loading time of 12h was 
allowed. Zeta potential measurements were performed using the ZetaPALS Zeta Potential 
Analyzer (Brookhaven Instruments Corporation, Austin TX), as described previously221). M. 
luteus was characterized in 1 X PBS-CHX-diacetate solution at and at 8·108 cells/ml. The 
influence of CHX on the zeta potential was studied over a range of concentrations from 0µg/ml 
to 1000µg/ml CHX in increments of 100 µg/ml. In order to correlate the zeta potential data with 
the amount of CHX found intracellular, the samples were recovered and centrifuged to separate 
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cells from the PBS-CHX-diacetate solution. The cells were resuspended in lysis buffer and 
placed in a 40 °C sonication water bath for 30 minutes. The cell fragments were centrifuged off 
subsequently and the absorbance of the supernatant after lysis was measured as described earlier 
in the direct measurement section. 
 CHX Retention 
To measure the retention of CHX over the course of five days 30 ml of a M. luteus cell 
suspension were centrifuged at 10000g. The supernatant was removed and replaced by 30ml of 
CHX-gluconate stock solution (2%w/v). Loading was allowed for 12 hours. The cells were 
separated by centrifugation at 10000g, the cell pellet was washed once with PBS and 
subsequently resuspended in 30 ml PBS buffer. First, five 1ml samples were taken and the cells 
were separated by centrifugation at 14000 rpm. The supernatant was removed and stored for 
analysis. The cell pellet of each sample was resuspended in 1ml lysis buffer and both supernatant 
and lysate were analyzed immediately using UV/Vis spectroscopy as previously described. The 
procedure was repeated every 24h for five days. 
 Thioglycollate Induced Peritonitis for ex vivo use of Neutrophils 
Syngeneic mice were used to isolate circulating leukocytes for loading with appropriate 
antimicrobials. Mice were injected with 2.5 ml of autoclaved, aged thioglycollate medium 
(Fisher Scientific, Waltham, MA) intraperitoneally. Twelve hours later, mice were placed under 
isoflurane anesthesia (2.0%-4.0%) and circulating neutrophils were isolated by peritoneal lavage 
with PBS. Following the procedure the mice were euthanized. 
 Flow Cytometry Analysis of Neutrophils 
The extracted neutrophil granulocytes were counted using a hemocytometer. The cells were 
centrifuged at 500g (accuSpin 3r, Fisher Scientific, Waltham, MA) resuspended in RPMI 
medium to match a concentration of 5•105 cells/ml (cut-off for the flow cytometer). A cell-pellet 
from a 1ml M. luteus suspension was exposed to a 0.5 mg/ml stock solution of rhodamine-B for 
12 hours. The cells were separated via centrifugation at 14000 rpm and washed with PBS until 
the supernatant is colorless and then resuspended in PBS. After counting the bacterial cells the 
suspension was diluted to a concentration of 5•107 cells/ml. 200 µl of rhodamine-B modified M. 
luteus suspension were added to 1ml of neutrophils in RPMI and the sample was incubated for 2 
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hours at 37°C. In preparation for analysis the sample was centrifuged at 500g and the supernatant 
was replaced with 1ml PBS. Flow cytometry (Guava easy cyte plus, Guava Technologies, 
Chicago, IL, Software: easy cyte 2.2.2) was used to determine the amount of neutrophils 
showing fluorescence from rhodamine-B. An unloaded neutrophil control group was used to 
calibrate the horizontal cutoff on a yellow florescence vs. side scatter readout and 5000 cells 
were counted per measurement. Each measurement was repeated three times. 
 PI-Annexin-V Assay to determine neutrophil survival 
Neutrophils were prepared as described in the previous section. M. luteus was loaded with CHX 
as described earlier, counted and diluted to a concentration of 2.5•108 cells/ml. Two sets (3h and 
6h incubation time) of neutrophil-samples (5 ml suspension per sample) were subsequently 
incubated with CHX-modified M. luteus with 10, 20 and 100 bacterial cells per neutrophil 
granulocyte (100 µl, 200 µl, 1000 µl respectively). The cell cultures were incubated for two 
hours at 37°C in a 50ml conical tube with filter cap. Then the protocol for the PI/annexin 5 
apoptosis assay was carried out 220) and the samples were analyzed via flow cytometry. An 
unloaded sample of neutrophils was used to calibrate the vertical and horizontal cutoff on a red 
fluorescence (PI) vs. green fluorescence (Annexin-V) readout and 5000 cells were counted per 
sample. Each measurement was repeated three times. 
 In Vitro drug delivery against E. coli and F. necrophorum 
The extracted neutrophils (PMN) were loaded with 20 bacteria per neutrophil (4-6·106 
neutrophils per sample). The samples were incubated at 37°C for two hours as previously 
described. Sample types were PMN + ML (Neutrophils + M. luteus), PMN + ML modified with 
CHX, PMN (Neutrophils + CHX-modified M. luteus) and RPMI buffer. 
A starter culture of E. coli was grown overnight from a single colony in LB broth containing 
Ampicillin at a final concentration of 50ng/ml and Nalidixic acid at a final concentration of 
12ng/ml.  0.1ml of the overnight culture was added to 5ml of fresh LB broth containing no 
antibiotics, and grown to and O.D.600 of 0.3. The bacteria were spun down to pellet out the 
bacteria. The bacterial pellet was resuspended in 1X PBS to achieve 1·107 CFU/ml. The bacteria 
were then incubated with 10% v/v complement inactivated mouse serum for 20 minutes at 370C 
to opsonize the bacteria. The opsonized bacteria were then mixed with equal amount of PMNs 
(1:1 MOI and 1:1 volume of each) and incubated at 370C for 90 minutes, on a rocker platform. 
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The tubes were then spun down at 5,000 RPM for 5 minutes, the supernatant was discarded and 
the pellet was resuspended in 100µl of 1X PBS. 100µl of 1% Triton was added to the 
resuspended pellet to lyse the eukaryotic cells, and was gently mixed to ensure that no bubbles 
were formed. This mixture was allowed to sit at room temperature for 5 minutes. 800µl of LB 
broth was added to the mixture to bring up the final volume to 1ml, which was then serially 
diluted and plated on LB agar plates containing a final concentration of 50ng/ml Ampicillin and 
12ng/ml Nalidixic acid to enumerate the bacteria. 
A starter culture of F. necrophorum subsp. necrophorum strain 8L1 was grown overnight from a 
single colony in Pre Reduced Anaerobically Sterilized Brain Heart Infusion broth (PRAS-BHI). 
0.3 ml of the overnight culture was added to 10ml of fresh PRAS-BHI broth and grown to an 
O.D.600 of 0.7.  The bacteria were spun down to pellet out the bacteria. The bacterial pellet was 
resuspended in 1X PBS to achieve 1·107 CFU/ml. The bacteria were then incubated with 10% 
v/v complement inactivated mouse serum for 20 minutes at 37°C to opsonize the bacteria. The 
opsonized bacteria were then mixed with equal amount of PMNs (1:1 MOI and 1:1 volume of 
each) and incubated at 390C for 90 minutes, on a rocker platform. The tubes were then spun 
down at 5,000 RPM for 5 minutes, the supernatant was discarded and the pellet was resuspended 
in 100µl of 1X PBS. 100µl of 1% Triton was added to the resuspended pellet to lyse the 
eukaryotic cells, and was gently mixed to ensure that no bubbles were formed. This mixture was 
allowed to sit at room temperature for 5 minutes in an anaerobic chamber. 800µl of PRAS-BHI 
was added to the mixture to bring up the final volume to 1ml, which was then serially diluted and 
plated on blood agar plates (Thermo Scientific), and incubated in an anaerobic chamber to 
enumerate the bacteria. 
 Loading of Doxorubicin (DOX) in M. luteus 
A DOX stock solution was prepared by dissolving 2.5 mg DOX in 50ml PBS in a 50ml-size 
conical tube. The M. luteus cell pellets described in the previous section are resuspended in 1ml 
of the 0.05 mg Doxorubicin/ml PBS buffer solution. The cell suspension was placed on the 
LabLine thermo rocker overnight. This procedure was repeated five times to create five samples. 
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Figure 3: Example for the setup of the 96 well plate for DOX analysis in the M. luteus cell lysate 
After 12-18h the samples were centrifuged (Eppendorf centrifuge 5415C, Germany) and the 
supernatant was replaced by 1ml of PBS buffer and washed once. To quantify the uptake of 
DOX in the cell pellet the loaded cells were lysed using the strong lysis buffer and a 40 °C 
sonication water bath (Cole-Parmer, Vernon Hills, IL) for 30 minutes. After exposing the cells 
for 40 minutes to the strong lysis buffer the sample was centrifuged at 14000rpm to remove cell 
fragments and the supernatant was kept for analysis. The amount of DOX in the supernatant was 
determined by UV/Vis spectroscopy (BioTek Synergy H1 micro-plate reader, Winooski, VT). 
The spectrum was measured from 400 to 500nm with a step size of 5nm. The samples were 
analyzed on a 96 well plate and 100µl were plated per sample. A calibration curve was 
established by measuring the absorption of DOX in PBS as well as in strong lysis buffer from 0 
to 50 µg in increments of 12.5 µg (3 repetitions for each increment). Both lysate (DOX in strong 
lysis buffer) and the supernatant after loading (DOX in PBS) were analyzed with the respective 
blanks and the amount of DOX was determined using the respective calibration curve. 
 DOX Retention 
To measure the retention of DOX over time 10 ml of a M. luteus cell suspension were 
centrifuged at 10000g (Thermo Scientific Sorvall Legend RT+ centrifuge, Waltham, MA). The 
supernatant was removed and replaced by 10ml of a 0.05 mg DOX/ml PBS solution for 12 hours. 
The cells were centrifuged off at 10000G, the cell pellet was washed once with PBS and 
subsequently resuspended in 10 ml PBS buffer. First, five 1ml samples were taken and analyzed 
immediately to serve as initial reference of the total amount of DOX loaded. The remaining 5 ml 
of DOX loaded cell suspension were placed on a shaker. After seven days the cells were 
centrifuged off and a 1 ml sample was taken from the supernatant and analyzed for its DOX 
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concentration. UV/Vis analysis was carried out as described above, with PBS as blank and using 
the DOX-PBS calibration curve. 
All samples were measured in groups of five repetitions to evaluate the standard deviation. 
 MTT assay for cell viability measurements 
M. luteus was loaded with DOX as described in the previous section. Mo/Ma cells were plated in 
concentrations of 8000-10000 cells per well in 100µl of RPMI1640 medium supplemented with 
10% fetal bovine serum one day in advance. With three different groups and ten repetitions for 
each group a total of 30 wells were plated in three rows of ten wells on a 96 well plate. Row one 
was the control group and received no additional treatment. Row two received 10µl of the 2*107 
cells/ml M. luteus suspension (20 bacterial cells/Mo-Ma cell). Row three received 10µl of the 
2*107 cells/ml DOX-modified M. luteus suspension (20 bacterial cells/Mo-Ma cell). The samples 
were incubated for 72 hours and the MTT assay was carried out according to reference219). 
 4T1 Cancer Cell Assay with Conditioned Medium 
The tumor cell line 4T1 from the mouse mammary gland adenocarcinoma were grown in 
PMI1640 medium supplemented with 10% fetal bovine serum (FBS; Sigma–Aldrich, St. Louis, 
MO). Cells were plated in concentrations of 8000-10000 cells per well with 100 µl RPMI 
medium for MTT assays. Three plates with four rows and ten filled wells each for a total of 120 
wells was prepared. Conditioned medium for the in vitro testing of released DOX from Mo/Ma 
cells on 4T1 cells was produced by plating 80000 loaded cells per well with 1.5 ml RPMI in five 
wells on a 24 well plate. Each well was incubated with 100 µl of an 8*107 bacterial cells/ml 
suspension of DOX-modified M. luteus. Two control groups were plated in similar fashion but 
were not incubated with DOX-modified bacteria. One control group received only RPMI 
medium and one received 100 µl of 0.05 mg DOX/ml PBS buffer solution. The medium was 
collected each day from each well and replaced with 1.5ml of fresh medium. The collected 
conditioned medium was then complemented with 1 ml fresh medium and added to 4T1 cancer 
cell cultures grown on a 96 well plate in portions of 100 µl. Each day the 4T1 cell vitality was 
evaluated by executing the MTT assay as previously described on one row on each of the 96-
well plates. The procedure was repeated over the course of four days. 
Simultaneously the fluorescence increase in the collected conditioned-medium was measured 
over the course of five days in an IVIS Lumina-II imaging system (Caliper Life Sciences) to 
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monitor the release of DOX from the Mo/Ma cells during the production of conditioned medium. 
After the Mo/Ma incubated with DOX-modified M. luteus produced conditioned medium they 
were lifted by trypsination and flow cytometry was used to determine the fraction of fluorescent 
Mo/Ma cells. The RPMI-control group was used to adjust the cutoff bar on the yellow 
fluorescence vs. side scatter readout. 
 DP 44 mt 
To solubilize DP 44 mt 1.8 mg were first dissolved in 20 µl of DMSO and vortexed for 30 min.  
9980 µl of PBS buffer (pH 7.4) were added subsequently and the sample was centrifuged to 
detect and separate the solution from possible insoluble parts. If no insoluble parts were detected 
by eye the solution was labeled as 0.18 mg DP44mt/ml PBS. 
Aliquots of 1ml were drawn from a M. luteus-PBS suspension and placed in 1.5ml Eppendorf 
reaction tubes for a total of five samples. They were centrifuged at 14000rpm and the supernatant 
was replaced by the DP 44 mt solution. After resuspending the cell pellet the samples were kept 
on the shaker overnight. After 12-18 hours the cells were centrifuged off at 14000rpm and the 
supernatant was stored for further analysis. The cell pellet was washed with PBS once and the 
washing supernatant was also stored for further analysis. The cells then were lysed with 1% 
Triton-X lysis buffer to release the loaded DP44mt into the lysis buffer and all samples were 
analyzed using UV/Vis spectroscopy (BioTek Synergy H1 micro-plate reader, Winooski, VT). 
The absorption spectrum was measured from 300nm to 400nm with a step size of 1nm. 
DP44mt’s peak at 322nm was used to determine the concentration of DP44mt in solution and the 
amount of DP44mt loaded per sample. 
 DP44mt Retention 
To measure the retention of DP44mt a 15 ml cell suspension was centrifuged and the supernatant 
was replaced by 10 ml DP44mt-PBS stock solution (0.18 mg/ml). After a loading period of 18 
hours the cell suspension was centrifuged and the supernatant was replaced by 15 ml PBS buffer 
pH 7.4. On day 0, 1 and 2 five 1 ml samples were taken and analyzed using UV/Vis 
spectroscopy. The plate reader settings were the same as described in the previous section. 
 DP44mt Analogue – CHX Conjugate 
The conjugate was synthesized following this procedure: 
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Coupling of thiosemicarbazone (N'-(Di-pyridin-2-yl-methylene)-hydrazinecarbodithioic acid 
methylester) (DP44mt analogue of the DP family) to chlorhexidine was done in DMF with two 
equivalence each of EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide), HOBT 
(Hydroxybenzotriazole) and 2.5 equivalence of DIEA (N,N-Diisopropylethylamine). The 
reaction solution was reacted for four days under argon. After the completion, DMF was 
evaporated by air oxidation. The synthesis product was a brown solid. 
The conjugate shows a decreased water solubility to an extent that the preparation of a stock 
solution with known concentration was impossible. To get an aqueous solution of the conjugate 
the synthesis product was first dissolved in pure DMSO and centrifuged to separate the solution 
from insoluble parts. 20 µl of the clear conjugate-DMSO solution were then added to 1 ml PBS 
which resulted in a precipitation of some material that was prone to stick to the reaction tubes 
wall. The sample was then placed on the rocker for 24 hours at 45 °C in order to re-solubilize the 
precipitate partially. After 24 hours the sample was centrifuged to separate the solution from 
remaining precipitate. The supernatant was of light brown color and was transferred to a new 
tube. Loading of M. luteus with the aqueous conjugate solution was similar to the loading with 
DP44mt. The sample preparation for analysis was again done with 1% Triton-% buffer and the 
lysate was analyzed spectroscopic. The conjugate’s stock solution of unknown concentration 
showed no specific peak but a very strong absorption in the region below 350 nm. Dilutions of 
the stock solution showed a specific peak at 290 nm. This was utilized to measure the retention 
of the conjugate over the course of 6 days. 
 Conjugate Retention 
To measure the retention 6 individual aqueous 1 ml conjugate solutions were prepared as 
previously described. All M. luteus samples were exposed to the conjugate solution for 18 hours 
after which the supernatant was replaced by PBS and the conjugate specific absorption at 290 nm 
was measured over the course of 6 days using one sample each day with 5 repetitions plated. 
 In vivo Studies 
 Preliminary toxicity Study 
Neutrophils were loaded with M. luteus modified with 1% or 2% CHX as described earlier in the 
in the in vitro tests against F. necrophorum. The loaded neutrophils were centrifuged at 500g for 
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30 minutes to separate them from the RPMI medium and resuspended in PBS to reach a 
concentration of 1*106 cells/ml. 
In order to determine whether chlorhexidine gluconate was toxic to mice, we conducted in-vivo 
toxicity assays. Briefly, ten week old BALB/c mice were given tail vein intra-venous (IV) 
injections containing approximately one million neutrophils carrying M. luteus loaded with either 
1% or 2% chlorhexidine gluconate. Additionally a control group was injected with PBS. The 
three groups were assigned three animals per group. The animals were observed for 5 days post 
challenge to see if they demonstrated any clinical signs of toxicity. At the end of 5 days, the mice 
were euthanized and their kidneys, liver, brain, lung, spleen and heart were fixed in 10% 
formalin for histopathological evaluation. 
 Mouse-treatment Study 
F. necrophorum subsp. necrophorum strain 8L1 was grown overnight from a single colony in 
PRAS-BHI. 0.3ml of the starter culture was added to 10ml of fresh PRAS-BHI broth and grown 
to an O.D.600 of 0.7. 1 ml of this culture was diluted 1:40 to achieve a final concentration of 
approximately 4*106 CFU/ml 222). 400µl of the diluted bacteria was injected intraperitonially 
into 10 week old BALB/c mice. The mice were observed for two days before they were treated 
with neutrophils carrying antimicrobial cargo. 
10 week old BALB/c mice were randomly assigned into 6 groups with 9 mice per group. On day 
zero, all mice were infected intraperitonially with an infectious dose of F. necrophorum. On day 
3 of the experiment, all mice were given intravenous tail injections containing 100µl of the 
following treatments or controls- mice in group 1 were treated with one million neutrophils 
containing M. luteus loaded with chlorhexidine, mice in group 2 were treated with one million 
neutrophils containing M. luteus loaded with doxycycline (4.4mg/kg body weight), mice in 
group 3 were treated with one million neutrophils containing empty microparticles, mice in 
group 4 were treated with one million neutrophils and mice in group 5 were treated with 1X 
PBS.  The animals were monitored for clinical signs for 5 days after treatment and were 
euthanized if any clinical signs developed. The mice were euthanized 5 days post treatment and 
all mice were examined post mortem for abscesses in the livers. Livers of the mice were weighed 
and homogenized in a tissue homogenizer for 1 min in modified lactate (ML) broth. The F. 
necrophorum bacterial load in the homogenate was enumerated using most probable number 
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(MPN) analysis223) using ML broth. Homogenized liver tissue samples were streaked on blood 
agar plates for bacterial isolation and identification using Rapid ANAII system (Thermo 
Scientific). Liver, lung and spleen were fixed in formalin for histopathological evaluation. 
 
 
 
Chapter 5 - Characterization of Loaded M. luteus, ex vivo Loading 
of Neutrophils and in vitro Drug Delivery Testing 
 M. luteus loaded with chlorhexidine 
 Characterization of the loaded bacterial cells 
The CHX-loaded Micrococcus luteus was analyzed qualitatively using the CHX specific UV/Vis 
absorption at 635nm wavelength. Figure 4 shows the CHX peak at 635nm is clearly visible in the 
loaded sample and the average absorption is increased by roughly 0.1 for equal bacterial 
concentrations of 8*108 cells/ml. 
 
 
Figure 4: Comparison of the M. luteus absorption with and without CHX. The loaded sample ● 
shows the distinctive peak for CHX at 635nm while the unloaded sample ● does not. 
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The amount of CHX loaded was determined by lysing the cells with a Triton-X/Tris buffer 
system in order to establish a mass balance. Samples that were needed for further experiments 
can be analyzed indirectly by measuring the CHX concentration in the supernatant after loading 
the cells and calculating the amount of CHX loaded via spectral subtraction of a CHX reference. 
Both methods have shown to be accurate with standard deviations under 10% of the measured 
value. The results show that 1.81 ± 0.11mg of CHX are taken up by an average 40mg/ml wet cell 
mass sample of M. luteus. This is an uptake of 9% of the initially provided amount of CHX 
(20mg/ml stock solution). No traces of CHX were found in the washing steps or the lysed cell 
fragments. 
The uptake of CHX loading also was observed over a 4h timeframe in one hour increments 
showing that with an increased loading time more CHX is taken up. The results however are not 
significant (p>0.05) and all samples for in-vitro and in-vivo experiments have been loaded for 
24h to ensure a steady state. 
 
 
Figure 5: Time resolved loading of M. luteus with CHX. While the average spectral absorption 
for intracellular CHX increases over time, the difference between the time steps is not significant 
(p>0.05) 
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Another method to assess CHX loading and, more importantly, where in the bacterial cell CHX 
is located is a correlation of zeta potential measurement and UV-Vis analysis of loaded CHX. 
Since the mechanism of action for CHX is governed by the attraction of the positively charged 
CHX molecule to the negative surface charge of the bacterial cell an increase of this surface 
charge can be measured. Figure 6 shows the increased zeta potential for a CHX-hydrochloride 
concentration from 0 µg/ml to 1000µg/ml loading stock solution in 100µg/ml increments. The 
data has been normalized to allow a nonlinear regression of the underlying logarithmic shape of 
this dataset. The zeta potential reaches from -32.86 ± 1.88 mV (0%) at 0µg/ml CHX to -9.63 ± 
2.22 mV (100%) at 1000µg/ml CHX. 
 
 
Figure 6: Zeta potential data (surface charge) for M. luteus loaded with CHX-hydrochloride over 
a range of concentrations from 0µg/ml to 1000µg/ml CHX. The data has been normalized (0%-
100% equals an increase of the zeta potential from-32.86 ± 1.88 mV to -9.63 ± 2.22 mV). 
 
We subsequently correlated the zeta potential data to the actual amount of CHX loaded into the 
cell as we detect it by lysing the cells and measuring the CHX concentration in the lysate. The 
detected linear correlation in Figure 7 suggests that most of the CHX is bound on the surface of 
the cells or integrated into the cell wall rather than taken up into the cells cytoplasm. If CHX 
would enter the cytoplasm a further increase of CHX concentration in the cell lysate would be 
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expected, while the zeta potential is maintained at its upper limit of roughly -10mV. However 
this is not the case. A possible explanation is that the negative surface charge has reached a level 
too weak to further attract the positively charged CHX molecules. 
 
 
Figure 7: Correlation of the measured zeta potential (x-axis) with the measured absorption of 
CHX in the lysate (y-axis). A linear trend with an R2 value of 0.9045 is visible. 
 
The ability of M. luteus to retain CHX it has taken up is vital to ensure that the neutrophil 
granulocyte’s quality as a drug carrier is not impaired by cytotoxic effects of released CHX on 
the way to the site of the infection. 
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Figure 8: Analysis of CHX retention in M. luteus over the course of 5 days. There is no 
detectable increase in the amount of free, extracellular CHX (average value over 5 days is 15µg), 
while the intracellular CHX stays constant at an average of 490µg. 
 
Figure 8 shows that after 5 days 5% of the loaded CHX are released by the cells into the buffer. 
Given the average lifetime of neutrophil granulocytes of 5.4 days 180) this presents a satisfying 
result in terms of protecting the carrier cell from cytotoxic CHX effects. 
 Neutrophil loading and survival ex-vivo 
To determine the ex-vivo neutrophil loading efficiency for modified bacteria, M. luteus was 
loaded with a fluorescent rhodamine dye. The neutrophil sample was analyzed via flow 
cytometry and compared to an unloaded neutrophil sample. Figure 9 shows that approximately 
70% of the neutrophil population had taken up the rhodamine-modified M. luteus after a 2h 
loading period. 
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Figure 9: Comparison of the yellow fluorescence of an unloaded neutrophil population with a 
neutrophil population loaded with rhodamine-modified M. luteus. 
 
Ex-vivo neutrophil survival during the loading phase is detrimental for this drug delivery 
mechanism. Neutrophil granulocytes don’t survive for more than a day ex-vivo and additional 
stress by exposure to bacterial sample can further reduce the survival time dramatically. It has 
been shown that phagocytic activity increases the oxygen consumption of neutrophils by the 
factor of two 224). Figure 10 shows that ratios of 10-20 bacteria per neutrophil granulocyte give 
reasonable survivability of the neutrophil when compared to the control group. If exposed to a 
ratio of 100 bacteria per neutrophil the survival drops below 10% for both time points. 
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Figure 10: Neutrophil survival after 3 and 6 hours for ratios of 10, 20 and 100 
bacteria/neutrophil determined by PI/annexin 5 apoptosis assay and flow cytometry. 
 
 Evaluation of Oxygen Consumption and Supply in the ex vivo loading procedure 
 
The loading ex vivo is carried out in a filter capped reaction tube with 18-20 million cells at the 
concentration of 1·106 cells/ml. The system is neither aerated nor mixed so oxygen transport 
occurs only at the air-liquid interface. This implies that the governing equation for oxygen 
transport into the system is Fick’s law for diffusion where the driving force for mass transport is 
the concentration gradient between the oxygen concentration in the interphase layer and the bulk 
liquid. 
If we assume steady state the accumulation term of the mass balance is zero and the mass 
balance becomes: 
 
𝐼𝑛𝑝𝑢𝑡 = 𝐶𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 
Or: 
Equation 1 
𝐴 · 𝐽 = 𝑂𝑈𝑅 
With: 
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Equation 2 
𝐽 = −𝐷
𝛿𝑐
𝛿𝑥
 
 J is the diffusion flux in mol/(m2·s) 
 D is the diffusion coefficient in m2/s 
 C is the concentration in mol/m3 
 X is the position in m 
 A is the surface area of the liquid 
The values of oxygen consumption (OUR) for phagocytosing monocytes, macrophages and 
neutrophils were obtained from the literature 224, 232). 
Wilke et al. (1955) 232) have developed a correlation to estimate the diffusion coefficient in 
liquids: 
Equation 3 
𝐷𝑂2 = 7.4 ∗ 10
−8 𝑇( 𝐴𝐻2𝑂 ∗ 𝑀𝐻2𝑂)
1
2
µ ∗ 𝑉𝑂2
0.6
 
 T is the absolute temperature in K 
 AH2O is an association parameter for the solvent (value = 2.26) 
 MH2O is the molecular mass of water 
 µ is the viscosity of water in centipoise (value = 0.682 cp) 
 VO2 is the molar volume of oxygen (value = 25.6 cm3/g-mole) 
The diffusion coefficient for oxygen at 37 °C was calculated to be 3.067·10-5 cm2/s, and is 
comparable to 234). 
The oxygen concentration on the liquid side of the gas-liquid interface, c*, can be described by 
the partial pressure of oxygen in the gas phase and the Henry coefficient for low oxygen 
concentrations 235): 
Equation 4 
𝑐𝑂2
∗ =
𝑃𝑂2
𝐻𝑂2
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 PO2 is the partial pressure of oxygen in the gas phase (value = 0.21 atm, partial pressure 
for oxygen in air) 
 HO2 is the Henry constant 
The Henry coefficient strongly depends on temperature and ion – concentration in the medium 
and has a range of 900-1300 bar*L/mol for media 235). Its temperature and salinity dependence is 
described by Benson and Krause (1984) 236) with following equation: 
Equation 5 
𝐻𝑂2 = 𝑒
(3.71814+
5596.17
𝑇 −
1049668
𝑇2
+𝑆(0.0225034−
13.6083
𝑇 +
2565.68
𝑇2
))
 
 T is the absolute temperature in K 
 S is the salinity at physiological level (value = 5) 
This gives a Henry coefficient of 53990 atm or 0.972 atm·m3/mol and a surface oxygen 
concentration c* of 0.216 mol/m3. 
Since the oxygen concentration in the bulk liquid is unknown the critical oxygen concentration 
for eukaryotic cell culture of 0.05% 237) of the saturation concentration was used for the bulk 
liquid concentration in Fick’s law. This is reasonable since we are interested in the onset of cell 
death due to hypoxia and want to compare literature values for the oxygen uptake rates (OUR) of 
monocytes, macrophages and neutrophils under phagocytic conditions with the oxygen transfer 
rate (OTR) into the system. 
Integrating Fick’s law and inserting upper and lower boundaries gives: 
Equation 6 
𝐽 = −𝐷
(𝑐𝑂2,𝑙 − 𝑐𝑂2
∗ )
(𝑥𝑡𝑜𝑝 − 𝑥𝑏𝑜𝑡𝑡𝑜𝑚)
 
 CO2,l is the lowest oxygen concentration in the liquid 
 C*O2 is the oxygen concentration in the liquid at the gas-liquid interface 
 Xtop is the height of the liquid column (0.046 m), Xbottom is 0 
J is 1.37·10-4 mol/(m2 s) and that gives an influx of oxygen of 8.21·10-8 mol/s when multiplied 
with the area of the gas-liquid interface of 5.73*10-4 m2. 
The following values of cell specific OUR for monocytes, macrophages and neutrophils with and 
without phagocytic stress were found: 
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Table 1: Oxygen consumption for different cell types under phagocytotic stress. Values were 
obtained from references 224 and 232. 
All values in 
molO2/(10-6 cells·s) 
Monocytes224) Macrophages232) Neutrophils224) 
No phagocytotic 
stress 
1.667·10-12 1.267·10-10-11 1.833·10-11 
Phagocytotic 
stress 
2.66·10-11 5.733·10-11 3.883·10-11 
 
For neutrophil samples with a total cell count of 20·106 cells as used in the neutrophil survival 
experiments this means a total oxygen uptake of 7.77·10-10 mol/s. This is two orders of 
magnitude below the supplying rate of oxygen so the increased oxygen uptake by neutrophils 
during phagocytosis is not the determining factor of cell survival. Instead other factors like auto-
cytotoxicity from the produced antimicrobial reactive oxygen species 238) or induced apoptosis 
239) from antigen recognition may be the driving force for neutrophil cell death and the limiting 
parameters for phagocytic capacity. 
 
 In-Vitro Results 
The delivery system was tested in vitro on E. coli and F. necrophorum cultures. In both cases the 
targeted bacterium was eradicated completely by the treatment group. Control groups containing 
neutrophils or neutrophils loaded with unmodified M. luteus reduced the bacterial count when 
compared to the medium-control group but failed to effectively battle the bacteria leaving viable 
CFUs in the range of 106-108. This drop in the CFU count can be attributed to the increased 
release of bactericidal reactive oxygen species from neutrophil granulocytes as shown by Reiss 
et al. 224) Figure 11 shows the results for in vitro tests of the drug delivery system on E. coli 
C600N.The CHX treatment group was able to eradicate all E. coli C600N so that in a CFU count 
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no colonies were found. Similarly Figure 12 shows the complete eradication of Fusobacterium 
necrophorum subspecies necrophorum by the cell based CHX delivery system.  Again the 
control groups containing live neutrophil granulocytes show a reduced CFU count that can likely 
be attributed to the bactericidal properties of the phagocyte. 
 
Figure 11: In vitro tests of the cell based CHX drug delivery system on E. coli C600N. Here E. 
coli C600N was exposed to the following test groups: A is the CHX - M. luteus – Neutrophil 
granulocyte delivery system, B is the first control group with Neutrophil granulocytes loaded 
with unmodified M. luteus, C is the second control group with just unmodified Neutrophil 
granulocytes and D is the third control group with plain RPMI culture medium. 
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Figure 12: In vitro tests of the cell based CHX drug delivery system on Fusobacterium 
necrophorum subspecies necrophorum. Here Fusobacterium necrophorum subspecies 
necrophorum was exposed to the following test groups: A is the CHX - M. luteus – Neutrophil 
granulocyte delivery system, B is the first control group with Neutrophil granulocytes loaded 
with unmodified M. luteus, C is the second control group with just unmodified Neutrophil 
granulocytes and D is the third control group with plain RPMI culture medium. 
 
 M. luteus loaded with doxorubicin 
 Characterization of the loaded bacterial cells 
Doxorubicin (DOX) proved to be easily water-soluble within the relevant concentration range of 
12.5 to 50 µg/ml. Although it is listed as an anthracycline antibiotic it was ineffective at killing 
or inhibiting M. luteus in the previously mentioned concentration range. Its bright orange color 
allows an easy first assessment of the success of the loading procedure. Loaded M. luteus will 
accumulate in a bright orange pellet at the bottom of the tube after centrifugation when 
previously exposed to a DOX-PBS solution for 24 hours. 
UV-Vis spectroscopy was chosen to determine the DOX concentrations since DOX is self-
quenching making fluorescence measurements inconvenient especially after loading, when DOX 
is confined to the volume of the cell. The strong association of DOX with the bacterial cell or 
cell fragments, even after using 1% Triton-X lysis buffer and 40 minutes of sonication, made it 
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necessary to use a stronger lysis buffer with 3% Triton-X and 1% SDS. This however alters the 
absorption response of DOX molecules when compared to the PBS buffer and makes it 
necessary to employ individual calibration curves for the respective buffer systems. Figure 13 
shows the exemplary absorption spectrum of DOX in PBS in the range of 400 – 600 nm and its 
peak maximum at 480 nm that was used to establish a calibration curve.  
 
Figure 13: Typical UV/Vis absorption spectrum for several DOX concentrations 
 
The spectrum for DOX in strong lysis buffer retains the distinctive peak and absorption 
maximum at 480 nm, the absorption signal itself however is dampened as shown in Figure 14, 
the comparison of calibration curves for the lysis buffer-DOX system and the PBS-DOX system. 
The standard error for the calibration is given in Table 2 since the error bars were too small to be 
visible in the graph. 
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Figure 14: Calibration curves for DOX in PBS and in lysis buffer. Lysis buffer reduces the 
absorption for samples of the same concentration by a factor of 3.3 
Table 2: Standard deviations for the DOX calibration curves 
Lysis buffer  - DOX 0.0014 0.0014 0.0023 0.0009 0.0011 
PBS - DOX 0 0.0096 0.0032 0.002 0.0064 
 
There are two parameters of interest at this stage: how much DOX has been loaded into the M. 
luteus cell sample and how well do these cells retain DOX. A mass balance for DOX was 
established showing the amount of DOX initially provided compared with the amount found 
intracellular after lysing the cells with strong lysis buffer and the amount of DOX that was not 
taken up and remained in the PBS buffer after the 24 hour loading period. No detectable amount 
of DOX was found in the washing step. 
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Figure 15:  Mass balance for doxorubicin loaded M. luteus. The difference between intracellular 
& unloaded sample compared with the initial DOX concentration is not significant. 
Measurements for DOX in lysis buffer resulted in a larger standard deviation, a behavior not 
seen for the calibration curve. Approximately 36% of the initially provided DOX was 
internalized by bacterial cells. 
 
A t-test shows no significant difference (p>0.1) between the sum of intracellular DOX and 
unloaded DOX compared to the reference, the initial DOX concentration provided. Samples 
measured in lysis buffer (Intracellular and reference DOX) are however associated with a higher 
error, a phenomenon not seen for the calibration curve. Approximately 36.5% of the DOX 
provided were cell associated and released only by using the strong lysis buffer. 
 Retention of DOX 
DOX retention by the bacterial cells is important to ensure the protection of neutrophil or 
monocyte/macrophage carrier cells. The retention was observed over a time period of seven days 
and showed that over this time period of the 20.8 ± 1.4 µg intracellular DOX 38% (7.9 ± 0.8 µg) 
were released into the buffer. 
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Figure 16: DOX retention over the course of seven days. The bacterial cells have released 38% 
of the initially internalized DOX. 
 
The bacterial ghost system for example loses 40% of its DOX payload within the first 24h. 
While still acceptable when compared to the work of Lubitz et al. 126, 127) this is a surprisingly 
high value given the strong association of DOX to the cells when we tried to release it with 
normal lysis buffer. DOX might need the interaction with bacterial DNA, of which bacterial 
ghosts are stripped, therefore causing the short retention time. The fact that DOX does not kill M. 
luteus as we had initially assumed might be point towards a mechanism to remove DOX from the 
cell. 
The amount of DOX (MW of doxorubicin hydrochloride: 579.98 g/mol) carried by a bacterial 
sample of 0.2 ml volume and 8.8*108 cells/ml (sample size applied later in the chlorhexidine-
mouse study) is 7.17 µM and exceeds the IC50 systemic concentration of 0.62 µM more than 60 
fold making M. luteus a very effective carrier for DOX 201), especially for a targeted drug 
delivery that confines DOX closely to the tumor boundaries. Compared with lysosomal carriers 
that typically exhibit a carrier to drug ratio of 1:10000 76) the bacterial carrier achieves a ratio of 
1:2.25•108. 
 In vitro cell assays of Mo/Ma cell survival 
The survival of the transport cell is paramount to the success of the delivery system. Mo/Ma cell 
survival was tested for bacteria and bacteria loaded with DOX to ensure that the exposure to 
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bacterial antigens as well as the drug carrying bacteria does not affect the Mo/Ma cells vitality. 
The cells were exposed to their respective samples for 72 hours and their survival was measured 
via MTT assay. The results are shown in Figure 17. 
 
Figure 17: MTT assay to determine the survival of Mo/Ma cell cultures when exposed to 
bacterial samples and bacteria loaded with DOX. While the viability decreases significantly for 
both sample types it remains at 80% after 72 hours. This is a sufficient value since Mo/Ma cells 
should be able to reach their target within 24 hours. 
 
Both samples, Mo/Ma + bacteria and Mo/Ma + loaded bacteria have a significantly decreased 
viability (p<0.01) but average viabilities of 80% when compared to the control group after 72 
hours are acceptable results since Mo/Ma cells should be capable of reaching their target in 24 
hours or less 165). 
 In vitro cell assays with 4T1 cancer cells and conditioned medium 
After a sufficient survival of Mo/Ma cells that had taken up DOX carrying bacteria was shown 
medium was conditioned by Mo/Ma cells loaded with DOX modified bacteria. After 24 hours 
the conditioned medium was complemented with fresh medium of the same volume and 4T1 
breast cancer cells were exposed to the conditioned medium. This leads to a significant decrease 
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in 4T1 cell viability when exposed to medium conditioned by the Mo/Ma + DOX modified 
bacteria group over the course of 4 days while the 4T1 control group maintains a viability of 
100%. The other control group, conditioned medium from Mo/Ma cells loaded with 12.5 µg/ml 
DOX directly, did not course a drop in 4T1 cell viability. 
 
 
Figure 18: The 4T1 breast cancer cell line is exposed to conditioned medium from Mo/Ma-DOX 
cells or Mo/Ma cells loaded with DOX modified bacteria. Only the conditioned medium from 
the Mo/Ma - bacterial carrier system was able to reduce 4T1 cell viability. It drops from 95% to 
less than 20% within 4 days. 
 
A possible explanation is that free DOX associates with components of Mo/Ma cells, particularly 
DNA and free nucleotides 208), so strongly that it isn’t released from the cells. The DOX specific 
fluorescence was measured in the medium to determine if DOX is released from the cells. 
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Figure 19: DOX released from Mo/Ma cells loaded with free DOX or DOX in a bacterial 
carrier. The amounts of DOX released from the bacterial carrier system are significantly higher 
than the DOX released from the bacteria free system. Data was acquired via IVIS fluorescence. 
 
The Mo/Ma DOX-bacteria system shows a higher release of DOX over the observed time 
course, confirming that free DOX is not easily released from Mo/Ma cells once taken up, while 
DOX taken up via a bacterial carrier is probably released through an exosome. This is 
furthermore confirmed via flow cytometry, showing that the fluorescence of loaded Mo/Ma cells 
decreases over time from initially 70% fluorescent cells right after the loading process to 20% 
fluorescent cells at day 5. 
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Figure 20: The fluorescence of Mo/Ma cells loaded with DOX-bacteria decreases over the 
course of five days as DOX is released from the cells. Flow cytometry registers DOX-specific 
fluorescent cells of the total Mo/Ma population. Initially 70% of the Mo/Ma population showed 
DOX-specific fluorescence. This value decreases to 20% after five days. 
 
 M. luteus loaded withDP44mt 
 Characterization of the loaded bacterial cells 
Solid DP44mt is of bright yellow color but stock solutions with solubilized DP44mt are colorless 
not allowing an easy assessment of the loading as it was the case for DOX. DP44mt is poorly 
water-soluble and two different methods were tested for solubilization. The first solvent tested is 
a 50%/50% mix of poly-propylene glycol (PPG) and PBS and allowed concentrations up to 0.1 
mg/ml DP44mt. The second system uses 20 µl of DMSO to dissolve the initial DP44mt crystals 
(up to 2 mg) and then dilute the sample with the desired amount of PBS making solutions with 
higher concentrations possible. DP44mt was tested for antibacterial activity and proved 
ineffective in killing bacteria, however the 50/50 PPG-PBS mix was toxic to bacteria reducing 
the CFU count from more than 400 countable colonies for M. luteus in PBS to 2. All following 
work used the DMSO-PBS system because of the higher maximum concentration. DP44mt 
shows a distinct peak in the UV/Vis absorption spectrum at 322 nm as shown in Figure 21.  
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Figure 21: Typical UV/Vis spectrum for various concentrations of DP44mt 
 
Similarly to DOX this distinct peak is used for a calibration curve to determine DP44mt 
concentrations in samples like cell lysates and supernatants of unloaded DP44mt. 
 
 
Figure 22: Calibration curve for quantification of intracellular DP44mt 
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
300 320 340 360 380 400
A
b
so
rb
ti
o
n
Wavelength in nm
0 mg DP44mt 0.045 mg DP44mt 0.09 mg DP44mt
0.135 mg DP44mt 0.18 mg DP44mt 0.225 mg DP44mt
y = 7.4611x + 0.0021
R² = 0.9992
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 0.05 0.1 0.15 0.2
A
b
so
rp
ti
o
n
DP44mt in mg/ml
58 
 
Table 3: Values for the DP44mt calibration curve including standard deviations 
DP44mt Calibration 
DP44mt concentration in 
mg/ml 0 0.036 0.072 0.108 0.144 0.18 
Average absorption 0.0138 0.272 0.5128 0.817 1.0746 1.3516 
StDev 0.011498 0.015556 0.008468 0.012021 0.015372 0.024037 
 
Again the parameters of interest are the amount of DP44mt loaded and the retention capabilities 
of the cell. The loading efficiency for a 0.18mg/ml stock solution is 8.8% with a total amount of 
16.8 ± 1.4 µg/sample loaded. 
 
 
Figure 23: The left image shows the mass balance for the loading process of DP44mt. The sum 
of DP44mt found in the various cell associated samples exceeds the initially provided amount by 
7.4 µg. The right image shows the spectra for the intracellular DP44mt and DP44mt in the 
washing step. While the signal is weak the specific peak for DP44mt at 320 nm can still be seen. 
 
The mass balance however shows a significant difference (p<0.005) of the sample parts that 
were exposed to cells when compared to the reference sample with a total amount of 197.2 ± 3.3 
µg DP44mt found in samples that were exposed to cells and the reference sample with 189.9 ± 
0.8 µg DP44mt. This results in a difference of 7.4 µg DP44mt, which are unaccounted for. 
The retention of DP44mt was tested over the course of three days showing that DP44mt is not 
well retained by M. luteus cells. While 16.8 ± 1.4 µg/sample can be found intracellular right after 
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the 24 hour loading process this value drops to 5.1 ± 0.6 µg/sample after 24 hours and after 48 
hours the amount of intracellular DP44mt is below the detection limit. Why the amount of 
extracellular DP44mt after 24 hours exceeds the amount of DP44mt initially associated with the 
cell sample (both in- and extracellular) by approximately 17 µg is unclear. 
 
 
Figure 24: DP44mt is not retained by M. luteus cells. The complete amount of initially 
intracellular DP44mt is released after 48 hours allowing the cytotoxic effects of DP44mt to affect 
the transporting Mo/Ma cells. 
 
DP44mt (molecular weight 285.37 g/mol) has an average IC50 of 0.03 µM for a total of 28 cancer 
cell lines tested. The amount initially loaded in the experiments here is the equivalent of 11.2 µM 
for a 0.2 ml sample, exceeding the average IC50 of 0.03 µM more than 370 fold allowing the 
system to transport substantial amounts of DP44mt. The poor retention however fails to protect 
the monocyte/macrophage carrier cells from the cytotoxic effects of DP44mt as will be shown 
later in the in vitro cell culture section. A DP44mt analogue-chlorhexidine conjugate was 
synthesized to exploit the excellent retention of chlorhexidine and combine it with the high 
cytotoxicity of DP44mt. 
 In vitro cell assay for Mo/Ma cell survival 
The MTT assay shows that bacteria loaded with DP44mt don’t have any protective effect 
compared to free DP44mt. Cell viability drops from 80% to 40% within 48 hours. The reason is 
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the insufficient retention of the drug by the bacterial cells allowing the released DP44mt to 
unfold its cytotoxic effects within the Mo/Ma cells. 
 
 
Figure 25: Mo/Ma cell viability observed over 72 hours. DP44mt is not contained by its 
bacterial carrier and shows similar cytotoxicity as the free DP44mt. 
 
 CHX-DP44mt analogue conjugate 
The synthesized conjugate showed extremely poor water solubility. In order to solubilize a 
fraction of the conjugate it was first dissolved in pure DMSO, which wouldn’t result in a 
complete dissolution of the conjugate. Part of the DMSO-conjugate solution was then added to 
PBS resulting in a partial precipitation of the conjugate. The precipitate free fraction of the PBS-
DMSO-conjugate system was then analyzed via UV/Vis and compared with the pure individual 
components to verify the quality of the synthesis product. The poor solubility made it impossible 
to establish a calibration curve for quantification since producing a stock solution of known 
concentration was impossible. Other than pure DP44mt the conjugate is an effective bactericidal, 
completely deactivating the M. luteus population. 
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Table 4: Bactericidal properties of the synthesized conjugate 
 
M. luteus in PBS M. luteus exposed to conjugate in PBS 
Cells/ml 2.80E+11 0 
StDev 5.97E+10 0 
 
CHX hydrochloride only absorbs in the region below 32nm while the DP44mt analogue has its 
peak maximum at 350nm. In the conjugate this results in a shift of the onset from the 
predominant CHX hydrochloride absorption from 320 nm to approximately 355 nm and tailing 
of the absorption up to 480 nm. This indicates that the DP44mt analogue has been linked to CHX 
hydrochloride.  
 
 
Figure 26: The left graph shows the UV/Vis spectrum for the conjugate while the right spectrum 
shows the spectra for the individual pure components. While the general shape of the conjugate 
absorption curve resembles the CHX-hydrochloride curve the conjugate spectrum is red-shifted 
in comparison due to the influence of the DP44mt analogue. 
 
The retention of the conjugate was measured over the course of six days by lysing loaded cells 
and measuring the spectra from 280 to 360 nm. While the conjugate showed an increased 
retention through a consistent absorption in the cell lysate compared to pure DP44mt it also 
showed a consistently high absorption for the conjugate in the extracellular buffer. A possible 
explanation is that the conjugate further precipitated during the 24 hour loading process or that 
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not all of the precipitate was removed. Overall the conjugates poor solubility in the solvents used 
was a major obstacle for a good characterization of conjugate loaded cells and made a 
quantification impossible. 
 
 
Figure 27: The conjugates retention in M. luteus was measured over the course of 6 days. 
Consistently large absorption for extracellular conjugate due to its poor water solubility make it 
unclear if the retention of the conjugate is better in comparison to DP44mt. 
 
Intracellular conjugate is found consistently over the course of six days, but it remains unclear if 
the retention properties have improved since higher concentrations of the conjugate were found 
in the extracellular buffer simultaneously. 
 
 Conclusions 
Chlorhexidine loaded bacterial samples perform well in all aspects. Due to the blue color of 
CHX-gluconate loading success can easily be determined from the color change of the cell 
pellet. Uptake is rapid and the cells are fully loaded within 4 hours. CHX is well retained by the 
cells providing good protection for the transporting neutrophil granulocytes. The zeta potential 
experiments have shown that CHX associates with the cell surface rather than being internalized. 
While this is unfortunate in terms of achieving the best possible loading by using the full volume 
of the cell, the in-vitro experiment show that the amount loaded is sufficient to kill gram negative 
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pathogenic bacteria. CHX is probably not internalized because of the lack of a driving force once 
most of the negatively charged surface positions are occupied. Ex vivo loading of neutrophil 
granulocyte transport cells was successfully tested. It is detrimental for neutrophil survival not to 
overload the cells with too many bacteria. In vitro drug delivery tests on E. coli and F. 
necrophorum were very successful and resulted in the complete eradication of the pathogen 
cultures. 
Doxorubicin is easily loaded into bacterial cells and, like CHX, loading success can be 
determined from the color of the cell pellet after loading due to DOX bright orange color. A 
strong lysis buffer using both Triton-X and SDS as detergents is required to release the full 
amount of DOX from the cells again. This results in larger errors in the DOX quantification 
because DOX seems to interact with the lysis buffer, which alters the absorption pattern. 
Bacterial DOX shows a better release from Mo/Ma cells when compared to free DOX loaded 
into Mo/Ma cells. This may be the result of an uptake/release via endosome/exosome for 
bacterial DOX rather than a diffusion through the Mo/Ma cells membrane and possible 
interaction with DNA or nucleotides for free DOX. Ma/Ma cells loaded with bacterial DOX 
were able to reduce 4T1 breast cancer viability to 20% of the initial level. 
The poor water solubility of DP44mt is likely the cause of numerous problems with the 
component or the later synthesized conjugate. The mass balance for DP44mt leaves a significant 
gap between the amount of DP44mt initially provided and the sum of DP44mt associated with 
various stages of the cell samples. It is not well retained by the bacterial cell and its absorption 
behavior is influenced when in contact with bacterial cells as shown in the progression of the 
retention experiment. A conjugate of CHX and a DP44mt analogue was synthesized to exploit 
the excellent retention characteristics of CHX and combine it with the high cytotoxicity of DP-
class iron chelators. This conjugate however shows even poorer water solubility and makes an 
accurate quantification impossible. Unlike pure DP44mt it is bactericidal and may be retained by 
the bacterial cell, although the amount of extracellular conjugate found during the 6 day retention 
experiment does not allow a definitive conclusion since the conjugate might be in an equilibrium 
between in- and extracellular concentration rather than attached to negatively charged elements 
of the cell as it was shown for CHX-gluconate. 
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Chapter 6 - In vivo Mouse Studies of the Cell Based Antibacterial 
Drug Delivery System Against F. necrophorum Infections 
 Preliminary mouse toxicity study 
 
Two in vivo studies were carried out. The first one was a small 9-mouse study to determine toxic 
side effects of the drug delivery system, particularly toxic effects from free M. luteus and 
chlorhexidine itself. 
The mouse behavior was observed but no signs of lethargy unusual grooming behavior was 
found. Kidneys, liver, brain, lung, spleen and heart were collected for a histopathological 
evaluation of the tissues and showed no signs of tissue damage from CHX mediated toxic side 
effects. 
 Mouse study for antibacterial drug delivery against F. necrophorum 
infections 
 
In the final in vivo mouse experiment the CHX treatment group showed significant results 
(p<0.05, Pairwise Two-Sided Multiple Comparison Analysis; Dwass, Steel, Critchlow-Fligner 
Method 225-227) against all control groups. Each mouse in the CHX treatment group received a 
dose of 0.056 mg CHX. The CFU count was reduced by an order of magnitude from an average 
of approximately 2·106 in the control groups to 1·105. The treatment group using doxycycline 
modified M. luteus showed significant results as well but the results might be distorted due to 
two early deaths in this group that raised the bacterial count for this particular group. Figure 28 
shows the CFU count results of homogenized and plated liver samples. 
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Figure 28: Results of the in vivo experiment. MP + CH is the treatment group containing 
neutrophils loaded with CHX modified M. luteus. MP + DOXY is the treatment group 
containing neutrophils loaded with doxycycline modified bacteria. The PBS group is the control 
group containing pure RPMI medium while PMN and PMN + MP represent the neutrophil 
control groups without and with unmodified M. luteus. 
 
A subsequent spectroscopic analysis of the mouse liver samples showed no traces of residual 
CHX five days after the treatment injection. The damage caused to an untreated liver by 
Fusobacterium necrophorum subspecies necrophorum can be seen in Figure 29 
 
0.00E+00
5.00E+05
1.00E+06
1.50E+06
2.00E+06
2.50E+06
3.00E+06
3.50E+06
MP+CH MP+DOXY PMN+MP PMNs only PBS
B
ac
te
ri
al
 B
u
rd
en
 in
 M
ic
e 
u
si
n
g 
M
P
N
66 
 
 
Figure 29: Image of a mouse liver from the PBS control group showing lesions caused by F. 
necrophorum subspecies necrophorum. 
 
 Conclusions 
The in vivo mouse treatment study shows that: 
 A non-pathogenic bacterium (Micrococcus luteus) can be used as a vector for efficiently 
loading neutrophils with drugs ex-vivo  
 Chlorhexidine (a broad spectrum disinfectant) or doxycycline (a tetracycline antibiotic) 
can be efficiently taken up and trapped by the bacteria 
 Mouse neutrophils containing the therapeutic cargo can kill Fusobacterium necrophorum 
in-vitro 
 Mouse neutrophils loaded ex-vivo with the M. luteus containing antimicrobial drugs can 
be used as vehicles for targeted therapy of liver abscesses in mice caused by 
Fusobacterium necrophorum 
Thus, the bacterium M. luteus is used as a liposome-like protective shell for the active ingredient, 
chlorhexidine. It protects the neutrophil granulocyte, our targeting carrier, from cytotoxic effects 
of the drug and enhances uptake via phagocytosis. Chlorhexidine is a potentially suitable 
bactericidal drug showing activity even against MRSA strains 228). Using neutrophils as delivery 
vehicle has the advantage of a rapid targeted delivery to an infection site due to a fast 
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inflammation response. This allows localized treatment with low drug dosages. The short 
lifespan of neutrophils 229) guarantees a quick release of the drug.  
It is intriguing that this cell-delivered antibacterial therapy was efficacious in the mouse model 
even though only a small amount of chlorhexidine was administered (less than 60 micrograms in 
1.3•106 number of neutrophils), and only one dose was administered.   Multiple daily injections 
of the cell therapy could improve the reduction of the CFU count and may have completely 
eliminated all bacteria.  It is also possible that the cell-based therapy discussed here could be 
further enhanced by combining two or more agents in the bacteria.  For example, silver has been 
shown to greatly enhance the efficacy of antibiotics, even in cases of drug resistance 230). 
Effective antibacterial drugs exist, even for multidrug resistant bacteria, but they are limited by 
severe toxicity issues. For example, colistin, a polymyxin antibiotic discovered more than fifty 
years ago but discontinued due to its toxicity is now again in the clinic to treat cystic fibrosis 
patients, for which there is no other recourse 231). If a good retention by the drug carrying 
bacterial cell is given, the approach presented here could allow such drugs to be used because 
cells are used as a Trojan horse to shield normal tissues and cells from the drug, and only very 
small amounts of the drug are required, due to a localized distribution. 
Bacterial resistance to antimicrobials is now a global threat to humanity.  The findings presented 
here may offer the prospect of a new armament in the perpetual arms race against multidrug 
resistant bacteria, since it utilizes a cell-based targeted approach for single or combinatorial 
delivery of antiseptics or antibiotics that would otherwise be toxic.  It is intriguing that a very 
small amount of drug only administered once can be leveraged into a therapeutic benefit when 
actively targeted to the lesion by neutrophils. 
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Appendix A - R-code for student’s t-test 
R-code used for students t-test: 
 
two.sample.t.test.with.summary.data=function(x1bar,x2bar,s1,s2,n1,n2, mu, 
                                             var.equal=FALSE, alternative ='less'){ 
  if( var.equal==FALSE ) 
  { se = sqrt( (s1^2/n1) + (s2^2/n2) ) 
    # welch-satterthwaite df 
    df = ( (s1^2/n1 + s2^2/n2)^2 )/( (s1^2/n1)^2/(n1-1) + (s2^2/n2)^2/(n2-1) ) 
  } else 
  { # pooled standard deviation, scaled by the sample sizes 
    se = sqrt( (1/n1 + 1/n2) * ((n1-1)*s1^2 + (n2-1)*s2^2)/(n1+n2-2) ) 
    df = n1+n2-2 
  } 
  tobs=(x1bar-x2bar- mu)/ se 
  if (alternative =='less') pvalue= pt(tobs, df=df) 
  if (alternative =='greater') pvalue= 1-pt(tobs, df=df) 
  if (alternative =='two.sided') pvalue= 2*( 1-pt(abs(tobs), df=df) ) 
  list(test.stat=tobs, pvalue=pvalue, alternative=alternative) 
} 
x1bar=#insert_value# ; x2bar=#insert_value#; s1=#insert_value#; 
s2=#insert_value#; n1= #insert_value#; n2= #insert_value#; mu=0 
two.sample.t.test.with.summary.data(x1bar,x2bar,s1,s2,n1,n2, mu, 
                                    var.equal=TRUE, alternative ='less') 
 
